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ABSTRACT
ABSTRACT
Antimicrobial  peptides (AMPs) participate in  the immunity of both animals 
and  plants.  In  mammals,  the  most  important  AMP  families  are  defensins  and 
cathelicidins. The only human cathelicidin, LL-37, is a 37-residue, α-helical, cationic 
peptide  with  a  direct  membranolytic  antibacterial  activity  and  various 
immunomodulatory activities.
The aim of  our  research  was to  establish a  procedure  based  on an  E.  coli 
knock-out mutant library in the search for mutations conferring altered susceptibility 
to AMPs. The library was created by random insertions of Tn5 transposon into the 
bacterial genome. The selection of low-susceptibility mutants and their identification 
was first tested with a Bac7-derived peptide, for which at least one interactor had 
been found. The procedure was then applied for the identification of mutations that 
modulate the susceptibility of  E. coli cells to LL-37 with the aim of dissecting the 
steps of the peptide's mode of action. The differences between the wild-type and the 
mutant phenotypes were characterised using assays determining the bacterial culture 
growth inhibition and killing, as well as cell binding and membrane permeabilisation.
In the majority of the isolated Bac7-resistant mutants, Tn5 was inserted in the 
sbmA gene, confirming previous findings that showed an essential role for the SbmA 
protein in the internalisation of Bac7, allowing it to exert its antimicrobial activity. 
Tn5 insertion in the gene  waaY, identified in 15 out of 20 resistant mutants 
selected with LL-37, lowered the peptide’s ability to inhibit bacterial growth and to 
kill  cells,  decreased  peptide  binding  to  the  bacterial  surface  and  membrane 
permeabilisation. However, it did not alter the susceptibility to other AMPs. WaaY 
encodes a specific kinase that phosphorylates the Hep II residue in the core region of 
bacterial lipopolysaccharide. The inactivation of this enzyme determines a decreased 
negative  charge  of  the  outer  membrane,  which  in  turn  causes  a  decrease  in  the 
peptide’s binding to the cell surface and in its antibacterial activity. The results reveal 
a putative LPS-binding site for LL-37 and stress the importance of its initial binding 
to the cell surface for antimicrobial efficacy.
The  established procedure  utilising  Tn5 mutants  in  the  search  for  bacterial 
mutations conferring resistance to AMPs, proved efficient and opened a previously 
unreported branch of research on the mode of action of the human cathelicidin.
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RIASSUNTO
RIASSUNTO
I  peptidi  antimicrobici  (AMP)  fanno  parte  dell'immunità  innata  sia  degli 
animali che delle piante. Le famiglie di AMP più importanti nei mammiferi sono le 
defensine  e  le  catelicidine.  L'unica  catelicidina  presente  nell'uomo,  LL-37,  è  un 
peptide  lineare  e  cationico  di  37  residui  con  una  conformazione  ad  α-elica,  che 
esercita un’azione microbicida diretta tramite permeabilizzazione di membrana. In 
aggiunta, il peptide è anche dotato di una serie di funzioni immunomodulatorie.
Lo scopo del lavoro è stato quello di mettere a punto una procedura che utilizza 
una libreria di mutanti knock-out di E. coli, ottenuta mediante inserzioni casuali del 
trasposone Tn5 nel genoma batterico, per cercare mutazioni che rendano i batteri 
resistenti  agli  AMP. La bontà del  metodo è stata  prima verificata  selezionando e 
identificando  mutanti  resistenti  al  frammento  1-16  del  peptide  Bac7.  Una  volta 
ottenuti i risultati attesi, la procedura è stata applicata all'identificazione di mutazioni 
che  modulino  la  suscettibilità  di  E.  coli a  LL-37,  con  lo  scopo  di  meglio 
comprenderne  il  meccanismo  d'azione.  I  fenotipi  wild-type  e  mutante  sono  stati 
caratterizzati usando saggi d'inibizione della crescita batterica, di killing e di capacità 
del peptide di legarsi ai batteri e di permeabilizzarli.
Nella  maggioranza  dei  mutanti  resistenti  al  peptide  Bac7  isolati,  Tn5  ha 
inattivato  il  gene  sbmA,  confermando  risultati  precedenti  che  avevano  portato  a 
dimostrare l'importanza della proteina SbmA per l'internalizzazione di Bac7.
Nel caso di LL-37, in 15 dei 20 mutanti resistenti selezionati il trasposone ha 
inattivato il gene  waaY, che codifica per una chinasi specifica per la fosforilazione 
del  residuo Hep II  della  regione  core del  lipopolisaccaride batterico.  La mancata 
fosforilazione  nei  mutanti  selezionati  riduce  la  carica  negativa  della  superficie 
batterica, che, a sua volta, diminuisce l'inibizione della crescita, il killing, il legame e 
la permeabilizzazione delle cellule da LL-37, ma non da altri peptidi, suggerendo che 
la modificazione abbia alterato specificamente l'attività di LL-37, rivelando un suo 
putativo sito di legame all’LPS e sottolineando l'importanza del legame iniziale alla 
superficie cellulare per l'efficacia battericida del peptide.
La procedura messa a punto per la ricerca di mutazioni che inducono resistenza 
agli  AMP è  risultata  efficiente  ed  ha  indicato  una  nuova  via  per  far  luce  sulla 
sequenza di eventi responsabile del meccanismo d'azione della catelicidina umana.
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INTRODUCTION
INTRODUCTION
1. Immunity and the immune system
1.1. Immunity as a key feature for survival
Regardless of their position in the trophic network, all organisms are involved 
in the fight for survival,  including search for nutrients,  avoiding being eaten and 
competitiveness. For this purpose, nature equipped them with an extremely broad 
range of means raising the probability of successful adaptation to the surrounding 
environment. From prokaryotic bacteriocins to fight the competitors, through high 
reproductive  capabilities  in  plants,  teeth,  claws  and  mimicry in  animals,  to  high 
intellectual abilities in humans, these features and mechanisms have proven to be 
essential in the course of evolution as we see them at work in the present day living 
entities.
However, multicellular organisms have another enemy to defend themselves 
against. Microbes, such as viruses, bacteria and eukaryotic parasites, pose a serious 
and constant threat to their physiological stability and integrity. Therefore, they need 
to be kept under strict control (in case of symbionts) or eradicated efficiently with 
minimal energetic expense (in case of pathogens). The set  of abilities to perform 
these tasks is called immunity and is exerted by the immune system.
1.2. Two types of immune response
There  are  two  types  of  immunity  employed  by the  organisms:  innate  and 
adaptive. The former type is the first line of defence, based on similar and repeatable 
reactions upon detection of the hallmarks of pathogenic cells  and structures.  The 
latter  offers  a  delayed but  memorisable  answer  to  specific,  often  non-pathogenic 
factors and involves a broad range of cells and tissues undergoing a fine regulation 
by various factors, including the elements of innate immunity.
1.3. Innate immunity
In light of a constant exposition of certain parts of a multicellular organism to 
the  surrounding  environment,  invariably  containing  many  different  groups  of 
microbes,  an  effective  barrier  needed  to  be  employed  that  would  act  rapidly by 
recognising structures typical of microorganisms and absent in hosts. Examples of 
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such  structures,  called  pathogen-associated  molecular  patterns  (PAMPs)  or  more 
generally MAMPs (microbe-associated molecular patterns), are presented in Table 1.
Table  1: Examples  of  molecular  patterns  of  microbes  and  pattern  recognition receptors  of  innate 
immunity.
Molecular pattern of 
microbe Source
Pattern recognition 
receptor of innate 
immunity
Principal innate 
immune response
dsRNA Replicating viruses Toll-like receptor
Type I interferon 
production by infected 
cells
LPS Gram-negative bacterial cell wall Toll-like receptor/CD14 Macrophage activation
Unmethylated CpG 
nucleotides Bacterial DNA Toll-like receptor Macrophage activation
N-formylmethionyl 
peptides Bacterial proteins
N-formylmethionyl 
peptide receptors
Neutrophil and 
macrophage activation
Mannose-rich glycans
Microbial 
glycoproteins and 
glycolipids
1. Macrophage mannose 
receptor
2. Plasma mannose-
binding lectin
1. Phagocytosis
2. Opsonisation, 
complement activation
Phosphorylcholine and 
related molecules
Microbial 
membranes Plasma C-reactive protein
Opsonisation, 
complement activation
Following Abbas and Lichtman (2003).
1.3.1. Epithelia
The first barrier to block the microbial invasion are the epithelial surfaces of 
skin,  mucosa,  gastrointestinal  and  respiratory  tracts.  Apart  from  their  purely 
mechanical function, they are capable of synthesising numerous peptides endowed 
with  microbicidal  properties  and  belonging  to  various  physiological  groups 
(Schauber and Gallo, 2009). Those regarded as the host defence peptides (HDPs) 
will be described in greater detail later in this work. The peptides may be synthesised 
not only by the cells residing in the surface tissues, such as keratinocytes (Frohm et  
al., 1997), sebocytes (Lee et al., 2008), exocrine glands (Murakami et al., 2002) and 
mast  cells  (Di  Nardo  et  al.,  2003),  but  also  by leukocytes  recruited  to  the  skin 
(Agerberth et al., 2000).
1.3.2. Complement
The complement system is a biochemical cascade involving over 25 proteins or 
their fragments, originating from plasma or cell surface, which leads to a generation 
of  molecules  able  to  coat  microbial  particles  through  the  recognition  of  their 
13/111
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characteristic structures (see Tab.  1). Among three ways of cascade activation, the 
alternative  pathway  and  the  mannan-binding  lectin  pathway  are  considered  as 
effectors of innate immunity (the third, classical pathway is triggered by antigen-
antibody complexes). The microbe coating by the elements of complement, chiefly 
C3b  and  C5b  (originating  from  C3  and  C5  precursors,  respectively),  is  called 
opsonisation and significantly promotes  phagocytosis  of the coated particles.  The 
elements C3a and C5a (of the same origin as C3b and C5b, respectively) are able to 
activate  neutrophils  and  mast  cells,  the  former  of  which  participate  in  innate 
immunity. Finally, several elements in the late steps of complement activation form a 
membrane attack complex (MAC) that perforates microbial membranes leading to 
cell death (Abbas et al., 2007; Markiewski and Lambris, 2007).
1.3.3. Phagocytes and NK cells
The two main types of cells involved in innate immunity act in different ways. 
Neutrophils  and macrophages  act  upon activation  by performing phagocytosis  of 
invading microbes and/or host cells infected by viruses. The activation is a reaction 
to  certain  cytokines,  secreted  by  cells  participating  in  both  types  of  immune 
response,  and to  the microbes  themselves.  NKs carry out  a  degranulation  to  kill 
microbes and do not need activation to exert their activity.
1.3.3.1 Neutrophils and macrophages
Human neutrophils (polymorphonuclear leukocytes) carry two major types of 
intracellular  granules,  specific  and  azurophilic,  that  contain  proteases  and  other 
antimicrobial  agents,  such  as  antimicrobial  peptides.  Their  life  span  is  only
approx. 6 h and after that time of circulation in blood they undergo apoptosis.
Macrophages,  originating  from  monocytes,  are  mononuclear  phagocytes 
containing numerous lysosomes and phagocytic vacuoles. They are evolutionarily the 
oldest and the most common effectors of innate immunity, possessing the ability to 
survive for longer times and to differentiate at the site of inflammation.
Recruitment of phagocytes starts with an increased expression of selectins on 
the surface of blood vessel endothelium near the infection site, that is stimulated by 
cytokines.  This  causes  the  phagocytes  to  “roll”  and  gather  on  the  endothelium 
surface  as  their  adhesion  molecules  interact  with  selectin.  Then,  the  cell  affinity 
increases  thanks to  the  interaction  of  phagocytic  integrin  with  its  ligands  on the 
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vessel  surface.  Finally,  chemokines  stimulate  the  cells  to  migrate  through  the 
endothelium  towards  the  infected  tissue,  following  the  increasing  chemokine 
concentration. Such accumulation of leukocytes is a hallmark of inflammation.
Phagocytosis of a microbe is possible after its positive recognition by several 
types of phagocytic surface receptors. They may recognise microbe-specific patterns 
through direct contact (see Tab.  1) or bind to different types of opsonins coating a 
hostile cell, such as some elements of the complement system (mainly C3b and C4b), 
lectins  and,  most  of  all,  IgG antibodies  that  induce  a  particularly  high  level  of 
response and, as a product of B lymphocytes, are one of the ways of employment of 
innate immunity effectors by the elements of adaptive immunity.
Ingested cells/particles are destroyed by several mechanisms upon the fusion of 
a  newly  created  phagosome  with  lysosomes  containing  antimicrobial  agents, 
including  proteolytic  enzymes  (elastase,  cathepsin  G),  several  types  of  reactive 
oxygen species  (ROS) and nitric  oxide  (Abbas  et  al.,  2007;  Hume,  2006;  Segal, 
2005).
1.3.3.2 Natural killer cells (NK)
The origin of NK cells is of lymphoid lineage but the name is taken from their 
characteristic ability to kill target cells with no need for external activating factors. 
Their  action is regulated by simultaneously generated signals from activating and 
inhibiting receptors. The activating receptors bind various antigens expressed on the 
surface  of  cells  infected  with  an  intracellular  pathogen  or  subjected  to  tumoral 
transformation. The inhibitory receptors are able to recognise class I antigens of the 
major histocompatibility complex (MHC I) that are a sort of an ID tag carried by all  
nucleated host cells and this ability allows NKs to keep healthy cells  intact. This 
feature is also useful for elimination of cancer cells with reduced MHC I expression, 
which would be “invisible” for other control factors like T cells.
The cytotoxic activity is exerted by the release of the content of intracellular 
granules. Several factors released towards the target cell cause its apoptosis, among 
which perforins realise membrane perforation and granzymes decompose caspases, 
essential factors for cell cycle progression, which leads to cell apoptosis.
Another important function of NKs is the release of IFNγ that promotes the 
activation of macrophages (Abbas et al., 2007; Topham and Hewitt, 2009).
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1.3.4. Cytokines in innate immunity
Cytokines  are  proteins  produced  by  the  cells  involved  in  both  types  of 
immunity that allow the interaction between these cells and constitute a locally and 
systemically active set of stimuli. They influence the release of other cytokines, may 
share the sites of synthesis and function (effect), and their production is regulated by 
positive  and negative feedbacks,  as  well  as  by a  variable  expression of  cytokine 
receptors on the effector cells.
Innate  immunity  utilises  several  types  of  those  interactors  to  modify  the 
activity  of  both  branches  of  the  immune  system.  The  cell  type  most  commonly 
functioning as a source of cytokines are macrophages, which makes them a universal 
stimulator of the immune response.
The  two  principal  innate  immunity  cytokines  are  TNF-α  (tumor  necrosis
factor-α) and IL-1 (interleukin-1), sharing the function of activation of inflammatory 
processes  in  endothelia,  generation  of  fever  in  hypothalamus  and  induction  of 
synthesis  of  acute  phase  proteins  in  liver.  TNF-α  alone  additionally  activates 
neutrophils, increases fat catabolism in muscles and induces apoptosis in many cell 
types.
Chemokines,  as  already  mentioned,  function  as  phagocyte  activators  and 
attractants of these cells (chemotaxis) to the infection site. Interferon-α and -β (IFN) 
are  important  factors  in  blocking viral  infections  by attenuating  viral  DNA/RNA 
expression and replication and by inducing MHC I-mediated presentation of viral 
antigens on the surface of the infected cells.
Other cytokines from the interleukin group synthesised by macrophages are 
enhancers of the adaptive immune response (Abbas et al., 2007; Hopkins, 2003).
1.4. Adaptive immunity
The range of  antigens  recognised by the  elements  of  adaptive  immunity is 
broader than that of innate immunity and expands also to those of non-pathogenic 
origin. A level of diversity this high is obtained by somatic mutations leading to the 
generation of extremely variable cell receptors and antibodies. The system is also 
able  to  memorise  certain  antigens  and  target  them  immediately  after  their 
reappearance with a higher level of response due to the clonal expansion of antigen-
specific  lymphocytes.  These  properties  make  this  highly  developed  and 
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phylogenetically newer type of immunity the vertebrates' most important mechanism 
to cope with microbe invasion. Being a very complex system and not the principal 
subject of this thesis, the elements of adaptive immunity will only be described to an 
extent necessary for the understanding of further parts of this section.
1.4.1. Cell-mediated immunity
T lymphocytes are the effectors of cell-mediated adaptive immune response. 
The group contains several cell types differing in function and identified by different 
surface antigens. The so called naive lymphocytes are functionally inactive cells with 
hypervariable antigen receptors (T cell receptors, TCRs) that circulate in blood and 
may be activated in lymphoid tissues. After the recognition by a naive lymphocyte of 
a  specific  antigen presented by an antigen-presenting cell  (see  1.4.3.),  the T cell 
becomes activated, proliferates and differentiates. Thus formed effector cell returns 
into the circulation.
The most important T cell group is that of the CD4+ T lymphocytes (Th, helper) 
as they are involved in universal stimulation of the immune system. Upon a contact 
with its specific antigen, either presented directly by a microbe or by a macrophage 
that ingested the microbe, Th lymphocyte secretes a series of cytokines intensifying 
phagocytosis, antibody production by B cells (see 1.4.2.) and the cytotoxic effect of 
the CD8+ lymphocytes (Tc, cytotoxic).
The latter cells act on specific targets endowed with the recognised MHC class 
I  antigen.  After  activation,  they  are  able  to  kill  infected  host  cells  through  a 
mechanism similar to that of NK cells or by binding the target cell's Fas receptor that  
initiates the process of apoptosis. They are an important factor in blocking the spread 
of viruses and intracellular parasites.
Memory T cells  are responsible for maintaining the recognition of antigens 
years  after  the  primary  exposure.  They  may  be  derived  from  both  of  the 
aforementioned T cell  types  and their  maintenance  in  tissues  depends on a  local 
production of specific cytokines (see 1.4.4.) (Abbas et al., 2007; Abbas et al., 1996; 
Barry and Bleackley, 2002).
1.4.2. Humoral immunity
This type of activity is based on antibodies and B lymphocytes that produce 
them.  Antibodies  (immunoglobulins,  Ig)  are  proteins  with  hypervariable  regions, 
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generated by somatic gene rearrangement in B cells, able to bind to their antigens 
with  a  very high  specificity  and  functioning  as  opsonins  and  markers  for  target 
destruction by phagocytes, but also as B cell receptors (BCRs).
Naive B lymphocytes carrying a variably rearranged BCR reside in a lymphoid 
organ and are constantly exposed to antigen presentation, either by freely circulating 
soluble particles or by specialised cells, APCs (see  1.4.3.). On the recognition of a 
compatible antigen and direct interaction with an activated Th cell, the B lymphocyte 
is also activated, proliferates and differentiates into a plasma cell secreting copies of 
an antibody capable of binding the presented antigen. Antibody gene rearrangement 
does  not  stop  at  that  point  but  continues  in  order  to  select  the  cells  producing 
antibodies with a higher, fine-tuned affinity to the given antigen (affinity maturation). 
Another  process,  called  isotype  switching,  leads  to  Ig  heavy chain  modifications 
determining different types of antibodies, typical for various stages and sites of the 
humoral immune response.
Some plasma cells  may survive for longer periods in lymphoid organs in a 
quiescent state. These so called memory cells enable a much faster and more efficient 
production  of  high  affinity  antibodies  after  a  repeated  infection  with  the  same 
microbe.
Immunoglobulins  bear  an important  function of stimulating the response of 
innate  immunity.  Fc receptors  on different  types of leukocytes bind to the heavy 
chains of the antibodies in complex with the antigen derived from targeted cells and 
particles. This induces a variety of phagocytic, cytotoxic and stimulatory reactions, 
depending  on  the  effector  type.  Some  products  of  complement  activation  can 
covalently bind the opsonising Ig's and help to isolate and deactivate potential threats 
(Abbas et al., 2007; Carter, 2006).
1.4.3. Antigen presenting cells (APCs)
APCs  are  necessary  for  targeting  CD4+ T  lymphocytes  and  partially  B 
lymphocytes against the antigens originating from cells and tissues to be sought and 
destroyed.  They  ingest  peptide/protein  antigens,  process  them intracellularly  and 
expose their fragments as a part of MHC class II antigens that present the molecular 
pattern to the immunity effectors.
The  most  common  and  most  specialised  APC type  are  the  dendritic  cells 
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residing in tissues usually affected and colonised by intruders. They have the ability 
to  ingest  not  only  microbes,  but  also  host  cells  infected  by  a  virus  or  those 
malignantly transformed. Furthermore, they present the latter antigens using MHC 
class I structures (cross-presentation) to enable the activation of CD8+ T cells. The 
presentation occurs in the lymphoid organs and, in case of B cells, is continued by 
the so called FDCs (follicular dendritic cells) as the affinity maturation occurs.
Other cell types capable of presenting target antigens to the immunity effectors 
are  macrophages  and  B  lymphocytes.  The  former  cell  population  expresses  the 
antigens of ingested microbes to Th cells, which in turn secrete IFN-γ that increases 
the rate of phagocytosis and antigen presentation in macrophages. B cells present the 
captured  soluble  antigens  and  their  presentation  is  necessary  for  Th-dependent 
antibody  production  (Abbas  et  al.,  2007;  Chen  and  Jensen,  2008;  Hume,  2008; 
Stockwin et al., 2000).
1.4.4. Cytokines
Cytokines utilised by adaptive immunity have usually local  effect  and may 
remain  undetectable  in  collected  blood  samples.  Their  principal  source  are  T 
lymphocytes.
Interleukin-2 (IL-2),  previously known as  T cell  growth factor,  is  the most 
versatile pro-proliferative factor for T, B and NK cells. In T cells, it also stimulates 
the production of other cytokines and increases pro-apoptotic activity of Tc.
Interferon-γ mainly increases the expression of MHC antigens of both classes 
and activates macrophages. It also switches the produced antibody isotype to IgG, 
promoting opsonisation and complement activation.
IL-4 and -5 are secreted by Th2 cell subset. IL-5 increases the production and 
activates eosinophils, leukocytes necessary for the eradication of parasitic worms. 
One of the IL-4's functions is the inhibition of macrophage activation by IFN-γ.
Transforming growth factor-β (TGF-β) is a common anti-proliferative factor of 
leukocytes that stimulates collagen synthesis in fibroblasts and tissue repair  (Abbas 
et al., 2007; Hopkins, 2003).
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2. Antimicrobial peptides
Antimicrobial  peptides  (AMPs)  are  an  important  component  of  innate 
immunity. They have been found in plants and in vertebrate and invertebrate animals, 
which indicates that they are an evolutionarily ancient mechanism of defence. They 
are endowed with antibacterial,  antifungal, antiviral and anticancer properties, but 
can have a broad range of physiological effects on the host organism as well. Their 
microbicidal activity is exerted through membrane permeabilisation and/or inhibition 
of intracellular targets (Andreu and Rivas, 1998). More than 1,000 of them have been 
described so far and they can be looked up in several online databases, e.g.:
http://www.bbcm.univ.trieste.it/~tossi/pag1.htm (Tossi A et al.)
http://aps.unmc.edu/AP/main.php   (Wang et al., 2009).
The  classic  definition  described  them  as  cationic,  mostly  linear  and 
amphipathic polypeptides composed of 10-100 amino acids with a molecular weight 
usually not exceeding 10 kDa. More recent findings made this definition somewhat 
obsolete by including larger polypeptides or anionic AMPs.
As for the sites of production and secretion, in plants the peptides have been 
found mainly in seeds and leaves. In invertebrates they are present in hemolymph, 
both free and inside the granules of hemocytes (phagocytes), and are secreted by 
epithelia of various location. Vertebrates synthesise AMPs in epithelia and leukocytes 
(Ganz and Lehrer, 1999). The latter issue will be described in greater detail further in 
this  section.  Many  other  peptides  and  protein  fragments  possess  antimicrobial 
properties,  such  as  some  cytokines  and  chemokines,  neuropeptides  and  peptide 
hormones (Brogden, 2005).
2.1. Classification of AMPs
Learning the structural diversity of antimicrobial peptides led to the creation of 
several  classification  systems  based  on  different  criteria,  such  as  origin,  charge, 
structural  conformation  (α-helical,  β-sheet),  prevalence  of  specific  amino  acids, 
presence and number of disulphide bonds (Fig. 1), and, finally, precursor similarity. 
Presently,  the  most  common  classification,  presented  here  following Kim  A. 
Brogden, divides AMPs into groups according to mixed criteria (Brogden, 2005).
Linear, cationic, α-helical peptides are a widespread group of AMPs. They are 
present  in  invertebrates  (Hancock  et  al.,  2006),  like  cecropins  in  Hyalophora 
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Figure 1: Structures of host defence peptides.
α-helical
(LL-37, SMAP29)
Pro-/Arg-rich
(Bac5, Bac7)
Trp-rich
(indolicidin)
with no disulphide bonds
with 1 to 4 disulphide bonds
β-sheet with 1 S-S bond
(brevinins)
β-sheet with 2 S-S bonds
(protegrin, tachyplesin)
β-sheet with 3 S-S bonds
(α-, β-, θ-defensin)
β-sheet with 4 S-S bonds
(insect defensin, plant defensin)
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cecropia moth  (Steiner  et  al.,  1981),  andropin  in  Drosophila (Samakovlis  et  al., 
1991) and melittin in honeybee (Dufourcq and Faucon, 1977), and in vertebrates, like 
pleurocidin in the winter flounder (Cole  et al., 1997), magainins in  Xenopus frogs 
(Zasloff,  1987),  cathelicidin-BF in  Bungarus snake  (Wang  et  al.,  2008),  myeloid 
antimicrobial  peptides  in  cattle  [BMAPs,  (Skerlavaj  et  al.,  1996)],  pigs [PMAPs, 
(Storici  et al.,  1994)] and sheep [SMAP-29,  (Skerlavaj  et al.,  1999)], and finally 
CAP18  in  various  mammals,  such  as  rabbit  (Larrick  et  al.,  1993)  and primates 
(Zelezetsky et al., 2006), including humans (Agerberth et al., 1995).
Similarly ubiquitous group are cationic peptides rich in a particular amino acid 
or a group of amino acids, such as the Pro-rich apidaecin and abaecin in honeybee 
(Casteels  et al., 1989; Casteels  et al., 1990), drosocin in  Drosophila (Bulet  et al., 
1993), the Bac family in ruminants (Gennaro et al., 1989; Shamova et al., 1999) and 
PR-39 in pigs (Agerberth et al., 1991), the Pro/Phe-rich porcine prophenin (Harwig 
et al., 1995), the His-rich human histatins (Kavanagh and Dowd, 2004; Oppenheim 
et al.,  1986), the Trp-rich indolicidin  (Selsted  et al.,  1992) and, recently deduced 
from genomes and cDNA, Ser/Gly-rich cathelicidins in salmonids  (Scocchi  et al., 
2009b).
Another important group included in this classification are anionic and cationic 
peptides containing disulphide bridges formed by cysteine residues. There may be 
one S-S bond [in brevinins, (Morikawa et al., 1992)] two bonds [in porcine protegrin 
(Kokryakov et al., 1993) and tachyplesin in horseshoe crab (Nakamura et al., 1988)], 
or three bonds, as in the family of defensins present in vertebrate species (Lehrer and 
Ganz, 2002) and insects (Lambert  et al., 1989) (more details on human defensins 
later in this chapter). More than three bonds are present in antifungal plant defensins 
(Thomma et al., 2002) and in a structurally similar peptide named drosomycin from 
Drosophila (Fehlbaum et al., 1994).
Finally, there is a group of anionic peptides, such as maximin H5 (Lai  et al., 
2002), several Glu/Asp-rich anionic peptides in sheep  (Brogden  et al.,  1997) and 
human dermcidin  (Schittek  et  al.,  2001),  which  seem to  exert  their  microbicidal 
activity as secondary to different principal activities, and their detailed characteristics 
are still to be elucidated (Harris et al., 2009).
A separate group consists of antimicrobial peptides derived from fragmented 
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proteins  or  of  antimicrobial  domains  of  larger  proteins.  The  examples  include 
lactoferricin  [a  fragment  of  lactoferrin  cleaved by pepsin  (Gifford  et  al.,  2005)], 
casein-derived  casocidin  from  bovine  milk  (Zucht  et  al.,  1995),  or  proteolytic 
fragments of ovalbumin (Pellegrini et al., 2004).
2.2. Host Defence Peptides
The  term  Host  Defence  Peptides  (HDPs)  is  often  used  as  a  synonym  of 
antimicrobial peptides but some authors consider HDPs as a subdivision of AMPs 
that  includes  only  gene-encoded  peptides  whose  only  known  function  is  the 
involvement  in  the  immune  response,  both  by direct  microbicidal  action  and by 
stimulation of the immune system. Apart from some of the aforementioned examples, 
such  as  anionic  peptides  or  antimicrobial  fragments  of  proteins,  all  the  peptides 
further considered in this thesis are HDPs according to the proposed definition and 
both terms will be used as synonyms.
2.3. Major physical properties of AMPs
2.3.1. Charge
AMPs are mostly cationic, with the net charge ranging between +2 and +18, 
and  it  is  one  of  their  key  features  necessary  for  prokaryotic  cell  selectivity.  As 
opposed  to  zwitterionic  and neutral  phosphatidylcholine  (PC)  which  is  the  main 
ingredient  of  eukaryotic  membranes,  prokaryotic  membranes  contain  acidic 
phospholipids like phosphatidylglycerol (PG), phosphatidylserine (PS) or cardiolipin 
(CL)  and  additional  superficial  anionic  compounds,  such  as  LPS  and 
teichoic/teichuronic acid in Gram-negative and Gram-positive bacteria, respectively. 
Thus, the content of such anions allows the electrostatic interaction with cationic 
AMPs (Yount et al., 2006). It has been shown that an increase of a peptide molecule's 
net charge leads to a more efficient killing of bacteria, but after exceeding a certain 
threshold,  it  reduces  the  efficiency  and  the  microbial  selectivity,  inducing 
physiologically undesired effects  such as hemolysis  (Dathe  et al.,  2001).  Anionic 
peptides endowed with bactericidal activity require metal ions, such as zinc, to kill 
bacteria. This suggests that the ions play a key role as mediators of the peptides' 
mode of action (Brogden et al., 1996; Harris et al., 2009).
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2.3.2. Amphipathicity
An  unequal  distribution  of  hydrophobic  and  hydrophilic  amino  acids 
(amphipathicity)  is  important  for  the  interaction  between  an  AMP molecule  in 
solution and the surface of a microbe. It is a feature of most AMPs, including those 
with  α-helical  and β-sheet  structures.  In  α-helices,  the  optimal  periodicity of  the 
amphipathicity  for  a  selective  antimicrobial  action  requires  the  presence  of  a 
hydrophobic residue every 3 to 4 amino acids and is then supported with electrostatic 
attraction between the peptide and the bacterial membrane. β-sheet peptides often 
form polar and non-polar surfaces thanks to their higher rigidity provided by S-S 
bridges. Amphipathicity of AMPs, just like their charge, has to be balanced to avoid 
undesirable effects, since a greater concentration of hydrophobic residues may lead 
to permeabilisation of neutrally charged host cells. In fact, overall hydrophobicity, 
usually around 50%, determines the ability to enter and permeabilise the lipid bilayer 
and may induce host cell lysis as well when too high (Yeaman and Yount, 2003).
2.4. Modes of action
As for their mode of action, AMPs are generally divided into the groups of 
“lytic” and “non-lytic” peptides. The former group, composed mostly of  α-helical 
peptides, primarily exerts membrane-permeabilising activity leading to the loss of 
ions, dissipation of the membrane potential, irreversible changes in the internal cell 
environment, eventual cell death and lysis. The latter group, while presenting weaker 
permeabilising activity, is rapidly internalised into the target cells and induces cell 
death through the inhibition of intracellular processes.
2.4.1. Membrane permeabilisation
The first of the three currently supported membrane permeabilisation models is 
the “barrel-stave” model  (Fig.  2A).  It  proposes  a  pore  formation  by a  bundle  of 
peptide molecules spanning the lipid bilayer and lining the hydrophobic core like 
barrel-staves. Even though it was historically the first model proposed, it is currently 
known to be true only in the case of alamethicin (Yang et al., 2001).
The “carpet” model  (Fig.  2B) was first described for dermaseptins  (Pouny et  
al.,  1992) and  then  for  several  other  AMP families,  e.g.  cecropins.  Membrane 
permeabilisation  in  this  model  occurs  in  a  detergent-like  manner,  leading  to  the 
formation of micelles. A peptide molecule is orientated parallelly to the membrane, 
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Figure 2: Models of membrane permeabilisation by AMPs: “barrel-stave” model (A), “carpet” model 
(B), “toroidal-pore” model (C) (Brogden, 2005).
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does not get completely inserted into the hydrophobic core and does not contact the 
hydrophilic  parts  of  other  peptide  molecules.  After  an  electrostatically  driven 
interaction  with  the  polar  phospholipid  head  groups,  the  peptide  places  its 
hydrophobic face towards the fatty acid chains and the hydrophilic face towards the 
surface.  Once  the  threshold  concentration  is  reached,  a  disintegration  occurs  by 
disrupting the local bilayer curvature and during that process transient pores may be 
formed (Shai, 2002).
In  the  third  model  called  the  “toroidal  pore”  model  (Fig.  2C),  peptide 
molecules form pores in the lipid bilayer as they do in the “barrel-stave” model.  
However, in this case they do not come into contact with the hydrophobic core, but 
rather form a continuous bend lined throughout its surface with the lipid head groups 
tilted to connect both leaflets of the membrane (Brogden, 2005). This model has been 
described e.g. for magainins, melittin and protegrins (Yang et al., 2001).
2.4.2. Cell penetration and intracellular interactions
2.4.2.1 Internalisation
Some  AMPs  that  do  not  present  highly  membranolytic  properties  can  act 
intracellularly.  The  internalisation  of  peptide  molecules  may  occur  via  several 
mechanisms.
For  instance,  a  transient  permeabilisation  effect  allows  the  crossing  of  the 
membrane  by  the  honeybee  AMP  hymenoptaecin,  but  with  no  long-lasting 
membrane damage and no synergy with the effects of the lytic peptides' mode of 
action (Casteels et al., 1993).
A type of cross-membrane passage using a stereospecific mechanism involving 
a  transporter-mediated  internalisation  has  been  proposed  for  two  Pro-/Arg-rich 
AMPs, active only against Gram-negative bacteria: apidaecin  (Castle  et al., 1999) 
and Bac7 (Podda et al., 2006). For the latter, an ABC transporter employment was 
proposed, since a mutation in the gene encoding SbmA, a putative element of an 
ABC transporter system, leads to a significant reduction in the uptake of Bac7 and 
other Pro-rich peptides by E. coli cells (Mattiuzzo et al., 2007).
Histatin-5, one of histidine-rich AMPs endowed with antifungal activity, binds 
a  protein  located in  the fungal  cell  envelope,  Ssa1/2,  that  functions  as  a  peptide 
receptor  and  may be  involved  in  the  internalisation  of  histatin-5  (Kavanagh  and 
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Dowd, 2004; Li et al., 2003).
2.4.2.2 Intracellular killing
Until now, three major target mechanisms have been found to be interfered by 
the cell penetrating AMPs.
Inhibition  of  cell  division  and  induction  of  filamentation  (abnormal  cell 
elongation) have been observed in several Gram-negative strains after the treatment 
with PR-39 (Boman et al., 1993) and indolicidin (Subbalakshmi and Sitaram, 1998). 
This is the effect of inhibition at various stages of DNA, RNA and protein synthesis. 
This action is exerted by such peptides like  α-helical pleurocidin and dermaseptin, 
the aforementioned PR-39 and indolicidin, and human defensin 1 (HNP-1, described 
further in this chapter) (Brogden, 2005).
Disruption  of  respiratory  mechanisms  leading  to  the  generation  of  reactive 
oxygen species is another killing mechanism, employed by histatins against fungi 
(Kavanagh  and  Dowd,  2004) and  by  microcin  J25,  an  antibacterial  peptide 
synthesised  by  E.  coli,  that  also  presents  RNA polymerase  inhibition  in  Gram-
negative bacteria (Bellomio et al., 2007).
Third  significant  target  is  the  chaperone  protein  DnaK,  that  is  bound  and 
inhibited by Pro-rich peptides, such as drosocin, pyrrhocoricin, apidaecin (Otvos et  
al., 2000) and Bac7. However, the in vitro interaction of the latter peptide with DnaK 
does not translate into an altered susceptibility of a dnaK-knock out strain of E. coli 
to the peptide (Scocchi et al., 2009a).
2.5. Mechanisms of resistance in bacteria
In the course of evolution microorganisms have developed strategies to evade 
or  compensate  the  antimicrobial  activity  of  HDPs.  They  can  be  exerted 
extracellularly, to destroy AMP molecules or prevent their initial interaction with the 
microbial  surfaces, or intracellularly,  usually to transport  the internalised peptides 
outside. Of course, the modifications are made to a limited extent in order not to be 
detrimental for the microbe (Yount et al., 2006).
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2.5.1. Extracellular mechanisms
Proteolysis  is  one  of  several  ways  in  which  bacteria  attempt  to  protect 
themselves from the microbicidal activity of AMPs. A well-known example is the 
outer membrane endopeptidase PgtE in Salmonella, similar to OmpT (Stumpe et al., 
1998) and protease VII in  E. coli and Pla in  Yersinia. PgtE is posttranscriptionally 
regulated  by  the  PhoP/PhoQ  regulon,  which  also  controls  other  resistance 
mechanisms (see later). PgtE does not confer resistance to β-sheet peptides with S-S 
bonds  because  of  their  rigid  conformation  (Guina  et  al.,  2000).  Other  proteases 
targeting  AMPs  are  expressed  in  such  bacterial  species  as  S.  aureus,  E.  coli,
P. aeruginosa (Yount et al., 2006).
External surface modifications affect the initial interaction between the peptide 
and  the  bacterial  cell.  A highly  electronegative  capsule  exopolysaccharide,  e.g. 
alginic acid in P. aeruginosa (Friedrich et al., 1999) or CPS (capsule polysaccharide) 
in Klebsiella pneumoniae (Campos et al., 2004), binds avidly to cationic AMPs and 
depletes them from the medium, protecting vital cellular targets. Tightly packed LPS 
(see  5.)  is  also  considered  a  mean  of  protection  from  AMPs  in  Gram-negative 
bacteria  and  has  demonstrated  to  be  impermeable  to  unmodified  dodecapeptide 
(Papo and Shai, 2005).
Cell  wall-  or  outer  membrane-associated  mechanisms  are  the  key  AMP-
countermeasures in Gram-positive and Gram-negative bacteria,  respectively.  In  S. 
aureus,  the  Dlt operon catalyses attachment of D-alanine onto teichoic acid.  This 
leads  to  a  decreased  anionicity  of  the  cell  wall  and  consequently  obstructs  the 
attachment of cationic AMP molecules (Collins et al., 2002). The PhoP/PhoQ system 
in Salmonella is responsible for upregulation of a series of active responses to AMPs 
(Gunn and Miller, 1996), such as the aforementioned PgtE localisation on the outer 
membrane  or  various  lipid  A modifications:  palmitoylation  (Guo  et  al.,  1998), 
deacylation (Trent et al., 2001) and aminoarabinose modification (Gunn et al., 1998), 
that make the outer membrane less anionic and less accessible to AMPs, but also 
downregulate the host signalling and PAMP recognition through TLRs (Kawasaki et  
al., 2004).
The  least  known  resistance  mechanisms  are  those  altering  the  plasma 
membrane, of which the most commonly described is the MprF-mediated system in 
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S. aureus (with homologues in several other species) leading to the substitution of 
standard anionic phospholipids with cationic lipids containing ornithine (Yount et al., 
2006).
2.5.2. Intracellular mechanisms
The intracellular mechanisms of resistance generally concentrate on removal of 
the internalised drugs from the cell by energy-dependent efflux pumps. These have 
been described in  many microbial  species  (Lawrence and Barrett,  1998).  Several 
pumps responsible for the removal of AMPs are known, such as a universal Mtr 
system in Neisseria, QacA in S. aureus, or ABC-transporters in fungi (Yount et al., 
2006), and they may be an element of integrated systems involving several aspects of 
AMP resistance (Tzeng et al., 2005).
3. Mammalian HDPs
The  number  of  genes  encoding  antimicrobial  peptides  in  mammals  varies. 
Therefore, the number and prevalence of certain peptide families in different genera 
are also varied. What is common for this class of vertebrates is the presence and role 
of defensins and cathelicidins as the principal HDPs.
3.1. Defensins
Mammalian  defensins  vary  in  sequence,  but  all  share  the  presence  of  six 
cysteine residues whose spacing and connectivity through disulphide bonds allows 
the division into the two main classes,  α- and β-defensins, and a small class of the 
circular  θ-defensins  (Lehrer  and  Ganz,  2002).  The  three-dimensional  structure 
consists of a triple-stranded antiparallel β-sheet and a short N-terminal α-helix (the 
latter absent in bovine defensins). In humans and some rodents both classes have 
been found, in rabbits and guinea pigs only α-defensins are present, while in cattle, 
sheep and pigs only the β-defensin class has been reported (Schneider et al., 2005).
In humans, the defensin genes are located mostly in the chromosome 8p21-23 
and consist of 2-3 exons coding for a precursor (prepropeptide) (Fig. 3). The signal 
peptide (pre-piece) is cleaved by signal peptidase and the pro-piece is removed by a 
proper processing enzyme prior to release, leading to the generation of a mature, 
active form (Hancock and Diamond, 2000).
29/111
INTRODUCTION
3.1.1. Human α-defensins
According  to  Schneider  et  al.,  five  α-defensin  genes  and  six  α-defensin 
molecules  are  known (HNP-1 and -2 derive  from the same precursor).  They are 
present predominantly in azurophilic granules of neutrophils, where they represent
5-7% of total protein content, and in Paneth cells, secretory cells in the epithelium of 
the small  intestine.  Their  main role  seems to be the killing of ingested microbes 
inside the phagolysosomes of neutrophils, but also the control of intestinal bacteria 
populations. HD-5 has a particularly broad range of tissue presence, being produced 
by  epithelia  of  the  female  reproductive  tract.  The  human  α-defensins  display 
antibacterial (both against Gram-positive and Gram-negative bacteria) and antifungal 
activity (Schneider et al., 2005).
3.1.2. Human β-defensins
The genes for β-defensins show a much higher level of variability, with only 
four  products  isolated  from  tissues  (hBD-1  through  -4),  but  with  many  more 
identified  transcripts  giving  rise  to  theoretically  functional  peptides  or  inactive 
products of pseudogenes (hBD-5 through -33) (Pazgier  et al., 2006). Most of these 
transcripts are encoded by genes located on the chromosomes 6 and 20, outside the 
first identified location (8p21-23) of human β-defensins (Crovella et al., 2005).
As  for  the  expression  sites,  they  include  epithelial  surfaces  of  respiratory, 
gastrointestinal and urogenital  tracts, comprising exocrine glands. hBD-3 has also 
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Figure  3: Gene structure of human  α-defensins (A) and  β-defensins (B)  (Hancock 
and Diamond, 2000, modified).
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been detected  in  skeletal  muscles,  heart,  skin  and neutrophils.  The transcripts  of 
further  β-defensins  have  been  identified  predominantly  in  testis  and  epididymis 
(Pazgier et al., 2006).
Among the best-known β-defensins (hBD-1 to -4), hBD-3 presents the widest 
target  spectrum,  comprising  Gram-positive  and  Gram-negative  bacteria,  fungi 
(Harder et al., 2001; Joly et al., 2004) and even enveloped HIV-1 virus (Chang and 
Klotman,  2004;  Quiñones-Mateu  et  al.,  2003),  whereas  hBD-1 and -2  are  active 
primarily against  Gram-negative bacteria  strains.  hBD-3 is  also apparently not as 
salt-sensitive as hBD-1 and -2, being able to exert  its microbicidal activity under 
physiological or pathologically hypertonic conditions (such as lungs of CF patients) 
(Harder et al., 2001).
The antimicrobial activity of human β-defensins is only one of their properties, 
as  they  are  also  powerful  immunomodulators.  They  possess  strong  chemotactic 
activity towards dendritic cells (see  1.4.3.) and memory T-cells (see  1.4.1.) exerted 
by binding to the chemokine CCR6 receptor  (Yang et al., 1999). This process also 
induces DC maturation, antigen uptake and presentation, and other adaptive immune 
responses  (Lillard  et al., 1999; Yang  et al., 2004). Interestingly, it has been shown 
that  artificial  hBD-3  variants  with  reorganised  disulphide  bonds  had  similar 
bactericidal  activity,  but  impaired  chemotactic  properties.  The  latter  activity  was 
completely absent in analogues with no S-S bridges, suggesting the importance of 
three-dimensional structure for chemotaxis (Wu et al., 2003). There are several other 
putative  roles  in  which  hBDs  might  be  involved,  including  keratinocyte 
differentiation, tumour development and tissue remodelling (Pazgier et al., 2006).
3.2. Cathelicidins
The term “cathelicidins” was first proposed by Zanetti et al. in 1995 to describe 
a  non-homogeneous  group  of  antimicrobial  peptides,  including  e.g.  PMAP-36, 
CAP18, human FALL-39 (later  renamed to LL-37) and bactenecins,  identified in 
mammalian myeloid cells and sharing a conserved preproregion in their precursor 
sequence  (Zanetti  et  al.,  1995).  In  the  recent  years,  several  cathelicidins  were 
predicted from genomic/cDNA or purified from fish and snake (Chang et al., 2005; 
Chang et al., 2006; Maier et al., 2008; Scocchi et al., 2009b; Wang et al., 2008).
Cathelicidins are evolutionarily related, despite a great variety of sequences of 
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the mature peptides (Tomasinsig and Zanetti, 2005). The pro-piece contains a domain 
that is highly similar to a porcine cathepsin inhibitor named cathelin (cathelin-like 
domain,  CLD).  The recombinant  CLD of  LL-37 inhibits  cathepsin  L,  a  cysteine 
protease (Zaiou et al., 2003), but surprisingly, a partial deletion of a loop in a CLD 
derived from the porcine protegrin-3 resulted in its activating effect on cathepsin L 
(Zhu  et al., 2008). There has been a positive selection of certain regions of CLD-
encoding sequence in the course of evolution,  which led to those differences and 
suggests  a  functional  divergence  of  this  fragment  across  different  species  (Zhu, 
2008).
A typical gene of this class consists of 4 exons and 3 introns, with the fourth 
exon coding for the mature antimicrobial peptide (fig. 4). The processing of a newly 
synthesised peptide molecule is similar to that of defensins (see 3.1.) and the known 
processing enzymes releasing the mature, active, 12-100 amino acid-long form are 
elastase and proteinase 3 (Scocchi et al., 1992; Sørensen et al., 2001).
From the structural point of view, active cathelicidins belong to various classes 
(see  2.1.), including  α-helical (SMAP-29, LL-37), Pro-rich (Bac5, Bac7), Trp-rich 
(indolicidin) and disulphide-bridged (protegrins) peptides (Zanetti et al., 2002). They 
present different spectra of antimicrobial activity (even within the same structural 
class), different killing mechanisms and physiological effects on the host organism. 
Their  common  properties  are  the  ability  to  sequester  endotoxin  and  various 
mechanisms of immunostimulation (Tomasinsig and Zanetti, 2005).
The only cathelicidin in humans is LL-37 and as it was our object of interest in 
the series of studies presented in this thesis, it will be discussed to a larger extent.
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Figure 4: Gene structure of mammalian cathelicidins (Hancock and Diamond, 2000, 
modified).
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4. The human cathelicidin
4.1. Genetics, expression and processing
LL-37, previously known as FALL-39, was initially predicted from a myeloid 
cDNA library and  synthesised  as  FA-LL-37  endowed  with  antimicrobial  activity 
(Agerberth et al., 1995). The following year, it was extracted from granulocytes and 
the  correct,  37  amino  acid-long  molecule  sequence  was  confirmed 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES)  (Gudmundsson  et  al., 
1996). It is encoded by the human CAP18 gene (hCAP18 or CAMP), located on the 
chromosome 3p21.3 and endowed with the standard 4 exon/3 intron structure, with 
the active C-terminal fragment comprised in the 4th exon, along with six additional 
N-terminal amino acids (Larrick et al., 1996).
The expression of the hCAP18 gene was first detected in neutrophils (Larrick 
et al., 1995), but it has later been described in the following cell types, tissues and 
body fluids (Dürr et al., 2006):
• leukocytes
• bone marrow
(myelocytes, metamyelocytes)
• skin of newborn infants
• numerous squamous epithelia
• nail
• sweat
• wound fluid, blister fluid
• ocular surface epithelia
• synovial membranes
• nasal mucosa
• lung epithelia
• developing lung
• bronchoalveolar lavage fluid
• salivary glands
• saliva
• gingiva
• colon epithelium and mucosa
• testis
• epididymis epithelium
• spermatozoa
• seminal plasma
• vernix caseosa
• amniotic fluid
The hCAP-18 protein, precursor of LL-37, stored in the specific granules of 
neutrophils (see  1.3.3.1), is cleaved on cell activation by proteinase 3, one of the 
serine proteases  of azurophilic  granules  (Sørensen  et  al.,  2001). Surprisingly,  the 
cathelin-like domain that seemed a collateral product of this cleavage, serving solely 
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as a protector of the host tissues from the cytotoxic activity of LL-37 (see later), 
turned out to possess some antimicrobial activity itself, showing how the evolution 
maximised the usefulness of the whole translation product (Zaiou et al., 2003).
Despite being the only human cathelicidin, LL-37 can generate several other 
derivative  peptides  with  antimicrobial  properties,  created  through  cleavage 
performed by proteases present locally in many tissues. They may have enhanced 
microbicidal effects but reduced immunostimulatory capabilities (see later), which is 
a proof of a posttranslational regulation of the broad range of LL-37's physiological 
functions (Burton and Steel, 2009).
The role of factors inducing the expression of the cathelicidin is under constant 
investigation. An important role has been assigned to vitamin D, produced in skin 
upon UV exposure, whose biologically active form (1,25VitD3) has multiple binding 
sites  in  the  hCAP-18  promoter  sequence.  Increased  bactericidal  activity  of 
macrophages  against  M.  tuberculosis has  been  linked  to  1,25VitD3-dependent 
induction of LL-37 expression. Other factors playing a role in its modification are 
commensal and pathogenic bacteria in the intestine, as butyrate produced by many 
symbionts increasing the expression of the peptide, and the MxiE virulence regulator 
in  Shigella pathogens,  which  leads  to  its  downregulation  (Nijnik  and  Hancock, 
2009).
Variations in the production of the cathelicidin have been reported in numerous 
diseases.  Upregulation  occurs  in  skin  inflammatory  disorders  (e.g.  psiorasis),  in 
gastric epithelia during  H. pylori infection, bronchoalveolar lavage fluid-associated 
disorders (e.g. cystic fibrosis) and several others. Downregulation has been observed 
in atopic dermatitis, enteric infections and in neutrophils during acute leukaemia. A 
complete absence of LL-37 in granulocytes and saliva has been observed in patients 
with morbus Kostmann (Dürr et al., 2006).
4.2. Structural properties
4.2.1. Conformation
LL-37 is  a linear molecule which assumes an α-helical  conformation under 
physiological  conditions.  In  general,  it  can  occur  in  4  different  structural  forms
(Fig. 5).
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The  free  (F)  form  is  an  unstructured  form  of  LL-37  in  water  at  µM 
concentrations.  It  can oligomerise and form α-helices with the increasing peptide 
concentration  (dominates  over  the  monomer  above  10  µM),  constituting  the 
aggregated (A) form, which may also be assumed in the presence of certain anions. 
The facility of a helix formation is caused by a specific layout of amino acid residues 
with acidic or basic side chains present every 3 or 4 residues, which stabilise the 
conformation.
Oligomers are prone to interact with the medium, e.g. human serum, whose 
molecules segregate them (S form) and alter their antimicrobial and physiological 
effects.  This  effect  may be exploited  by the host  organism to minimise  the self-
cytotoxicity.
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Figure  5:  Schematic  representation  of  alternative  structural  forms  for
α-helical AMPs (Zelezetsky and Tossi, 2006).
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Lastly,  the  membrane  bound  (M)  form  also  depends  on  the  molecule's 
amphipathicity, as the hydrophobic face comes into contact with and immerses into 
the  lipid  bilayer,  and  the  polar  side  faces  the  solvent  (Johansson  et  al.,  1998; 
Zelezetsky and Tossi, 2006). It has been recently found, that in this state the peptide 
adopts a helix-break-helix conformation, with both the N- and C-termini unstructured 
(Porcelli et al., 2008).
A comparison of the tendency to assume F- and A-forms by LL-37 and its 
orthologues in primates, and their affinity to anionic and zwitterionic membranes, 
suggest  a  preferential  reduction  of  the  antimicrobial  activity  in  the  human 
cathelicidin (more prone to aggregate), but also a simultaneous enhancement of its 
binding capabilities to various host cells (Morgera et al., 2009).
4.2.2. Charge and amphipathicity
Both  of  these  properties  have  a  substantial  impact  on  the  antimicrobial 
efficiency of AMPs (see  2.3.). In case of LL-37, 16 of 37 residues are charged at 
physiological pH, with 11 positive and 5 negative charges resulting in the net charge 
of  +6.  This  enables  electrostatic  interactions  with  anionic  microbial  surfaces  and 
decreases the affinity to neutral host cells.
The amphipathicity, as mentioned above, is necessary for a peptide molecule to 
insert between the apolar chains of the membrane lipids while remaining in contact 
with the polar medium. LL-37 has the “hydrophobic angle” of approx. 160°, which 
means that a little less than half of the helix circumference is apolar (Fig. 6). The N-
terminal fragment does not present well-defined amphipathicity (Dürr et al., 2006).
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Figure 6: Helical wheel diagram for LL-37 showing the region 12-
29  as  an  amphipathic  helix.  N-  and  C-terminal  residues  are 
unstructured (Burton and Steel, 2009).
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4.3. Physiology
4.3.1. Direct and indirect antimicrobial activity
The human cathelicidin is active against a broad range of microorganisms. Its 
minimal  inhibitory  concentrations  (MICs)  have  been  established  against  many 
species of Gram-positive and Gram-negative bacteria, Spirochetes and yeasts. As an 
effective  lytic  peptide  (see  2.4.1.),  LL-37  performs  a  rapid  permeabilisation  of 
bacterial cells. Two modes of membrane perforation have been proposed as the most 
probable for this peptide. First, the carpet model of a detergent-like disintegration of 
membranes was suggested (Oren et al., 1999). It was later opposed by the toroidal-
pore  model,  denying  the  detergent-like  fragmentation  of  the  lysed  membrane 
(Henzler  Wildman  et  al.,  2003).  Some  recent  results  indicate  that  the  exact 
mechanism may depend on the lipidic content of the membrane (Porcelli et al., 2008) 
and differs  even  between  the  orthologues  of  LL-37 in  primates  (Morgera  et  al., 
2009).  In the fungal  membranes,  LL-37 forms large pores allowing the efflux of 
molecules of up to 40 kDa (den Hertog et al., 2005).
An obstruction of biofilm formation by  P. aeruginosa has been recorded at 
concentrations lower than bactericidal, thus the antimicrobial efficiency seems to be 
supported by the inhibition of a potential defence mechanism in bacteria (Overhage 
et al., 2008).
4.3.2. Immune system stimulation
Other-than-microbicidal activities of hCAP-18/LL-37 were noticed quite early 
and by far have become the fastest growing branch of knowledge on this peptide.
Binding and neutralisation of bacterial LPS, one of the most potent stimuli of 
the immune system, was among the first physiologically important features described 
(Larrick  et  al.,  1995).  Sequestering  of  LPS  leads  to  a  significant  decrease  in
LPS-induced TNF-α and nitric oxide release by macrophages (see 1.3.4.) (Zughaier 
et al., 2005). LL-37 can attack free aggregated LPS, but can also compete with LPS 
bound to its co-receptor (CD14) present on the surface of macrophages, inducing 
dissociation of LPS complexes and thus attenuating cytokine release by those cells 
(Rosenfeld et al., 2006).
As other important HDPs, LL-37 possesses chemotactic properties that are not 
affected  by  the  presence  of  serum.  It  chemoattracts  both  T-lymphocytes  and 
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neutrophils  (see  1.3.3.1),  the latter  of which form a sort  of positive feedback by 
releasing more cathelicidin on stimulation.  The peptide has also been reported to 
induce the maturation of dendritic cells (see 1.4.3.) and degranulation of mast cells 
(that also produce LL-37).  Chemotactic effects  occur via interaction with at  least 
three types of receptors, either by a direct activation or by transactivation (Bowdish 
et al., 2005; Dürr et al., 2006).
LL-37 has been indicated as an important factor in wound healing, either by 
being a product of dividing epithelial cells, an inducer of migration of keratinocytes 
or a putative growth factor/signalling molecule in epithelia. Angiogenic properties 
have also been observed by applying LL-37 in both in vivo and in vitro experiments. 
One  of  the  cathelicidin-binding  receptors  has  shown  to  be  a  mediator  of 
neovascularisation (Dürr et al., 2006).
4.3.3. Cytotoxicity
Some undesired negative effects of the generally cytotoxic properties of the 
human cathelicidin have been observed. A considerable level of haemolytic activity 
has been reported by Oren et al. which may be explained by putative importance of 
hydrophobic  interaction  with  otherwise  zwitterionic  (uncharged)  membranes  of 
erythrocytes  (Oren  et  al.,  1999).  What  is  more,  a  moderate  dose  of  LL-37 
administered to LPS-treated rats relieved the effect of sepsis, whereas a higher dose 
decreased the survival rate which might have been caused by the cytotoxic effects of 
the peptide (Fukumoto et al., 2005). According to a recent publication, evolutionary 
changes in the sequence of the unique cathelicidin in primates may have emphasised 
the  ability  to  form aggregates  and  shifted  the  role  of  the  peptide  to  that  of  an 
immunomodulator (Morgera et al., 2009).
4.4. Resistance in bacteria
Several existing ways of bacterial defence from HDPs have confirmed to be 
effective against LL-37. The most common mechanism of resistance is a proteolytic 
degradation of peptide molecules by extracellularly secreted proteases (see  2.5.1.). 
Among four enzymes of common pathogens reported by Schmidtchen et al. (2002), 
three of them belong to the M4 peptidase family and possess similar specificities:
P. aeruginosa LL-37-specific elastase,  Enterococcus faecalis gelatinase and the 50 
kDa metalloproteinase of  Proteus mirabilis.  Streptococcus pyogenes also degraded 
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the LL-37 cathelicidin  (Schmidtchen et al., 2002). In  S. aureus, two enzymes have 
been tested for the efficiency of LL-37 degradation: a metalloproteinase (aureolysin) 
and a glutamylendopeptidase (V8 protease). The former cleaves three peptidic bonds 
in the peptide molecule causing its complete deactivation, whereas the latter cleaves 
only  the  Glu16-Phe17  bond  and  the  so  formed  C-terminal  retains  much  of  the 
original peptide's activity (Sieprawska-Lupa et al., 2004).
Haemophilus  influenzae,  a  resident  pathogen of  the  upper  respiratory tract, 
expresses an unusual structure, phosphorylcholine (ChoP), which is exposed to the 
exterior  on  over  90% of  LPS  molecules.  It  reduces  the  anionicity  of  the  outer 
membrane and thus helps to mimic the zwitterionic eukaryotic membranes, which 
leads to a 1,000-fold increased survival of the bacteria treated with LL-37 (Lysenko 
et al., 2000).
5. Bacterial LPS
Lipopolysaccharide  (LPS) is  an  essential  ingredient  of  the  outer  membrane 
(OM)  in  Gram-negative  bacteria,  exposed  towards  the  cell  exterior,  providing 
mechanical  and chemical  protection to  the cell,  stabilising  the  overall  membrane 
structure and possessing a unique set  of biological properties. Although there are 
many variations in its content and in intramolecular connections of its ingredients, 
the type of LPS molecule found and described in enterobacteria is considered the 
“classical” one and will be discussed below.
5.1. Structure
LPS is a 10-20 kDa molecule composed of three main parts joined together in a 
chain, starting in the outer leaflet of the OM and finishing with an externally exposed 
saccharidic polymer (Fig. 7) (Magalhães et al., 2007). It is anionic and amphiphilic, 
may  form aggregates  of  varied  morphology  and  is  often  firmly  associated  with 
proteins and lipids of the OM (Wilkinson, 1996).
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5.1.1. Lipid A
Lipid A (Fig. 7A), which anchors the LPS molecule in the outer membrane, is 
the most conserved element of lipopolysaccharide and its variations are one of the 
bases of bacterial taxonomy. Lipid A is composed of two β-1,6-linked D-glucosamine 
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Figure  7:  Chemical  structure  of  endotoxin  from  E.  coli O111:B4.  The  letters 
represent:  (A) Lipid  A;  (B) Core  oligosaccharide (inner and  outer  core);  (C)  O-
Antigen. Abbreviations: (Hep) L-glycerol-D-manno-heptose; (Gal) galactose; (Glc) 
glucose;  (KDO)  2-keto-3-deoxyoctulosonic  acid;  (NGa)  N-acetyl-galactosamine; 
(NGc) N-acetyl-glucosamine (Slightly modified from Magalhães et al., 2007).
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(GlcN) residues, covalently linked to four 3-hydroxy-acyl  substituents with 12-16 
carbon  atoms  via  amide  and ester  bonds  (Magalhães  et  al.,  2007).  The  species-
specificity of lipid A is characterised by polar appendages to the phosphate residues, 
present at the 1st carbon of GlcN I and the 4th carbon of GlcN II, and by the number, 
identity and location of further fatty acyl groups linked to the four 3-hydroxy-acyl 
residues,  the  latter  of  which  are  represented  in  enterobacteria  by  (R)-3-
hydroxytetradecanoic acid (Wilkinson, 1996).
5.1.2. Core oligosaccharide
Core oligosaccharide (Fig.  7B) can be divided into two separate subregions: 
inner and outer core.
The inner core is composed of 2 or 3 residues of 2-keto-3-deoxyoctulosonic 
acid (KDO), the third of which may be substituted by another monosaccharide e.g. 
galactose, and of three L-glycerol-D-manno-heptose (Hep) residues, two of which 
are phosphorylated (Hep I and Hep II).
The outer core presents some variability, even between different strains of the 
same species. In E. coli, there are five types of the outer core, named K-12 and R1 
through R4, differing in the content and connectivities of 5 monosaccharidic residues 
(e.g. glucose, galactose) and in the ligation site of the O-polysaccharide (Raetz and 
Whitfield, 2002).
5.1.3. O-Antigen
The  O-Antigen  (or  O-Polysaccharide)  (Fig.  7C)  is  a  chain  of  4-40 
oligosaccharides  containing  3-8  monomers,  mostly  glucose  and  galactose 
(Magalhães et al., 2007). This neutral polysaccharide, covalently attached to the LPS 
core, presents a high degree of variability between bacterial strains and species and is 
highly antigenic.  Its  uniqueness also makes it  an important  identifier  of bacterial 
strains (Wilkinson, 1996).
5.2. Genetics of LPS synthesis
Since the subject of the research presented in this thesis largely regards LPS 
genetics, some information on the genes and their products involved in the synthesis 
of this compound will be presented.
The formation of lipid A relies on a series of independent lpx genes. The main 
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molecule is formed in a sequence catalysed by the LpxA-LpxC-LpxD-LpxB-LpxK 
enzyme cascade. Then, WaaA attaches two Kdo residues of the inner core to GlcN II, 
and finally LpxL and LpxM add acyl side-chains to those already present at the GlcN 
II (Raetz and Whitfield, 2002).
The assembly of the core oligosaccharide depends on the genes from the waa 
region.  The  attachment  of  the  first  two  Kdo  residues,  performed  by  WaaA,  is 
followed by addition of Hep I and Hep II by WaaC and WaaF, respectively (Gronow 
et al., 2000). The third Kdo residue is present only in some core types (K12 and R2) 
and is added by the product of the  waaZ gene, present only in the strains carrying 
those core types (Frirdich et al., 2003). Inner core synthesis is finally completed by 
three enzymes: WaaP that phosphorylates Hep I, WaaQ that adds Hep III as a lateral 
residue to Hep II, and WaaY that phosphorylates Hep II  (Yethon et al., 1998). The 
formation of the outer core is initiated by the addition of a glucose (Glc I) to Hep II  
of  the  inner  core  by  a  conserved  glucosyltransferase  WaaG.  The  genes  of  the 
transferases  adding  subsequent  monosaccharidic  residues  of  the  outer  core  vary 
according to the core type (waaB, waaO, waaR, waaU in K-12), but still share a high 
homology and are found in the same loci of the enterobacterial genome (Raetz and 
Whitfield, 2002).
The O-Antigen biosynthesis depends on the rfb gene cluster that is thought to 
have been acquired by E. coli through a horizontal gene transfer, since it shares some 
segment  similarity with that  of the  Shigella genus  (Stevenson  et  al.,  1994).  This 
polymorphism is reflected in extremely varied forms of O-antigen. The synthesised 
O-Antigen is joined with the Lipid A core fragment by the WaaL ligase (Whitfield et  
al., 1997).
5.3. Physiological effects of LPS
Being  the  most  external  interface,  LPS  plays  an  important  role  in  the 
interactions between Gram-negative bacteria and the environment. It is liberated by 
the cells at all cell-cycle stages and after cell death, which combined with its extreme 
thermal  stability  makes  LPS  an  efficient  pathogenicity  factor  (Magalhães  et  al., 
2007).
Lipid  A is  the  major  agent  responsible  for  the  rapid  and  massive  immune 
response to free LPS molecules that got in  contact  with immunity effectors.  The 
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molecules  are  first  bound  by an  acute  phase  protein  called  LPS-binding  protein 
(LBP) and the complex is then recognised by one of the Toll-like receptors, TLR4, 
along with its co-receptor CD14, which initiates signalling cascades that induce the 
expression  of  proinflammatory  cytokines  and  adhesion  molecules  in  endothelial 
cells, and the activation of macrophages (see  1.3.3.). This parallel reaction leads to 
the  clinical  state  of  sepsis  and  may be  life-threatening  due  to  such  pathological 
symptoms  as  hypotension,  endothelial  barrier  dysfunction,  excessive  leukocyte 
adhesion and disseminated intravascular coagulation (Dauphinee and Karsan, 2006).
Highly  specific  O-Antigen,  the  outer-most  bacterial  cell  structure,  is 
considerably immunogenic, allowing a precisely targeted control of symbionts, e.g. 
those inhabiting the intestine, performed by adaptive immunity. Conversely, a contact 
with an unknown serotype upon infection may result in a disease state (Nagy and Pál, 
2008).
6. Antimicrobial peptides as therapeutics
6.1. Existing approaches
Numerous clinical trials have been applied to three best-studied examples of 
peptides  intended to be used as topically applied agents against  local,  superficial 
bacterial infections.
Pexiganan,  a  22-amino  acid  synthetic  analogue  of  magainin  II,  has  been 
verified as an efficient antibacterial agent in vitro (Fuchs et al., 1998), but it was only 
moderately successful,  and comparable  to  an  orally  administered  antibiotic,  as  a 
cream  applied  on  mildly  infected  diabetic  foot  ulcers.  However,  one  of  the 
advantages of this application was no generation of resistance in treated pathogens 
(Lipsky  et  al.,  2008).  The  effect  was  not  sufficient  enough  for  pexiganan  to  be 
approved by FDA.
In phase III studies of the efficiency of iseganan, an analogue of protegrin-1, 
the peptide did not prevent the ventilator-associated pneumonia (VAP) in ventilated 
patients  (Kollef  et  al.,  2006) and  did  not  reduce  stomatitis  or  ulcerative  oral 
mucositis in patients receiving stomatotoxic therapy (Giles et al., 2004), even though 
previous studies showed a 1,000-fold reduction of microflora associated with the 
latter disease in healthy patients (Mosca et al., 2000). Clinical trials were stopped in 
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2004 due to elevated occurrence of VAP and higher mortality in patients, and the 
development  of  iseganan as  an  anti-infective  agents  was abolished  (McPhee and 
Hancock, 2005).
The third and, by now, the most promising attempt is omiganan, an indolicidin 
analogue, rapidly eradicating in vitro bacteria and fungi most often causing catheter-
related  bloodstream  infections  and  various  cutaneous  infections  (Fritsche  et  al., 
2008a;  Fritsche  et  al.,  2008b;  Sader  et  al.,  2004).  This  peptide  is  now awaiting 
registration.
6.2. Surpassing the in vivo limitations
Antimicrobial activity of the peptides  in vivo is hindered by several factors, 
such as sequestration by plasma content or degradation by proteases, produced either 
by the host or by the pathogens.
Numerous strategies have been developed to modify peptide structure in order 
to  make  them  less  susceptible  to  degradation.  These  include  size  reduction, 
modification of termini (acetylation, amidation), incorporation of non-natural amino 
acids (e.g. D-amino acids), amino acid swapping within the protease cleavage sites 
and finally cyclization of peptide molecules
To ameliorate the bioavailability and delivery rates, peptide molecules can be 
coupled  with  protective  structures,  such  as  polyethylene  glycol  (PEG)  moieties, 
liposomes,  or  even  nanotechnology-generated  “smart”  polymeric  microspheres, 
releasing the drug only under certain physiological conditions (Oyston et al., 2009).
6.3. Structural studies and target determination
The knowledge necessary to appoint novel drug candidates among AMPs may 
be obtained using different approaches.
Structural studies, concerning physicochemical properties of the peptides that 
influence their interaction with membranes or other model systems (e.g. cell wall 
elements),  provide  us  with  essential  information  on  the  mode  of  action  and  on 
possible  modifications  to  increase  the  microbicidal  efficacy  of  AMPs.  Structural 
definition of the peptides can be obtained by using such techniques as NMR, ATR-
FTIR, CD, neutron scattering and atomic force spectroscopy, offering different levels 
of resolution. The effect on living cells may be analysed through flow cytometry and 
visualised using electron and confocal microscopy. Finally, the stages of peptide-cell 
44/111
INTRODUCTION
interaction  may  be  dissected  by  employing  free  and  peptide-linked  fluorescent 
molecules,  plasmon  resonance  and  electrical  measurements  of  membrane 
conductance and capacitance (Zelezetsky and Tossi, 2006).
Other approaches utilise molecular biology techniques to determine microbial 
targets/interactors  of  known  AMPs  and  bacterial  response  elements.  This  is 
particularly useful in case of the peptides possessing putative internal targets.
One  example  of  such  research  was  based  on  the  determination  of  a 
transcriptional profile of S. aureus treated with hBD3 and on subsequent knock-out 
of the most upregulated genes in this model. This led to the indication of several 
processes impaired by hBD3 (active transport of metabolites, energy generation) and 
of  an  ABC  transporter  (VraDE)  responsible  for  counteracting  membrane  stress 
generated by the peptide (Sass et al., 2008).
A more straightforward procedure developed by Scocchi  et al. involved the 
generation  of  point  mutations  in  E.  coli and  selection  of  the  mutants  on  a  solid 
medium  containing  Bac7  (a  bovine  Pro-rich  cathelicidin)  at  an  inhibitory 
concentration. The mutations were identified by transforming wild-type cells with 
genomic libraries of the isolated resistant mutants, selection of the transformants on 
Bac7-enriched  solid  medium and  identification  of  the  genomic  fragments  in  the 
plasmids conferring resistance on the transformed wild type. This way, a putative 
ABC transporter SbmA (inactivated in some of the resistant mutants) was proposed 
as  an  internalising  agent  for  Bac7  (Scocchi  et  al.,  2008),  and  the  peptidase 
PtrB/OpdB  (upregulated  in  other  resistant  mutants)  demonstrated  the  ability  to 
degrade the peptide (unpublished data).
7. Summary
Antimicrobial  peptides  are  an  important  element  of  host  defence  against 
pathogenic microbes. With a vast repertoire of forms and functions, they constitute 
an  extremely  interesting  and  promising  branch  of  contemporary  biomedicine. 
Constantly increasing knowledge of their  structure and interactions  with both the 
target and the host cells allows us to explain how the nature managed to solve the 
problem of a quick, innate friend-or-foe identification and immediate reaction to the 
invasion of pathogenic microorganisms.
Analysis of structure-activity relationship of the peptide molecules, elucidation 
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of their modes of action and identification of potential target structures in microbes 
may  help  to  create  new  weapons  against  the  emerging  drug-resistant  infections 
plaguing the modern medicine.
LL-37 could be considered a candidate for a novel antimicrobial agent due to 
its  broad spectrum of activity.  Gaining knowledge of its  interactors and potential 
resistance mechanisms in bacteria might be a useful addition to the structural studies, 
for  the  purpose  of  engineering  a  degradation-  and segregation-resistant  molecule 
with  a  sufficient  level  of  microbicidal  activity,  reduced  host  cytotoxicity  and  a 
desired level of immunomodulating activity.
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AIMS OF THE STUDY
We attempted  to  adapt  and improve a  commercially available  procedure  of 
generating a library of E. coli knock-out mutants, carrying random single insertions 
of the Tn5 transposon in their genomes, for the search of those mutations that confer 
on bacteria a decreased susceptibility to antimicrobial peptides. This procedure was 
meant to be a high-throughput screening method, developed in order to appoint novel 
bacterial interactors of AMPs and expand our knowledge on their modes of action, 
potentially  useful  for  drug  design.  The  method  might  be  expanded  to  over  60 
bacterial  species,  applicable  with  Tn5  mutagenesis,  whose  majority  constitutes 
concerns in the ongoing war against pathogenic infections.
Once  established,  the  method  was  then  applied  for  the  elucidation  of  the 
mechanism of action of the human cathelicidin LL-37 against E. coli cells, so as to 
indicate  the  weak points  in  bacterial  physiology that  have  not  changed  over  the 
evolution and allow this antimicrobial peptide to act. Such information might then be 
used for targeting those points in the generation of novel peptide-based antibiotics.
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1. Bacterial cultures
1.1. Microbiological media
Luria-Bertani (LB) broth and Mueller-Hinton (MH) broth
LB and MH broth were prepared from 25 g and 21 g of dehydrated medium 
(DIFCO),  respectively,  dissolved  in  1  l  of  double-distilled  water  (MilliQ)  and 
autoclaved.
SOB and SOC media
To  compose  SOB  medium,  20  g  of  bacto-tryptone,  5  g  of  yeast  extract 
(DIFCO), and 0.5 g NaCl were dissolved in 800 ml of water, 10 ml of 0.25 M KCl  
were added, pH was set to 7.0 using 1 M NaOH, the solution was then brought to 1 l 
and  autoclaved.  SOC medium was  prepared  by supplementing  SOB with  sterile 
MgCl2 and glucose at the final concentrations of 10 mM and 20 mM, respectively.
High-salt phosphate-buffered saline (HS-PBS)
High-salt  PBS  was  prepared  by  dissolving  1.2  g  of  Na2HPO4,  0.22  g  of 
NaH2PO4•H2O and 23.4 g of NaCl in 1 l of water. After sterilisation in autoclave the 
solution was supplemented with sterile MgCl2 (final concentration: 10 mM).
Solid media
Solid LB and MH media were prepared using 15 g of agar as gelling agent per 
1  l  of  appropriate  medium.  Approx.  15 ml  of  LB/MH-agar  were  shed into  Petri 
dishes, left to solidify and stored at 4°C.
Antibiotics used in solid and liquid media
Stock and final concentrations of antibiotics applied in the presented studies 
are shown in Tab. 2.
Table 2: Antibiotics used in the presented studies
Antibiotic
Stock solution Concentration
in the mediumConcentration Storage
Ampicillin 100 mg/ml in water - 20°C 75 µg/ml
Kanamycin 100 mg/ml in water - 20°C 25-50 µg/ml
Tetracycline 15 mg/ml in 50% ethanol/water - 20°C 15 µg/ml
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1.2. Growth conditions and bacteria storage
Cultures on solid media were set up by spreading bacteria using inoculation 
loop or spreader and subsequent bottom-up overnight incubation of Petri plates in an 
incubator at 37°C.
Liquid  overnight  (o/n)  cultures  were  prepared  by  transferring  a  minimum 
quantity or a single colony of solid culture into 5 ml of medium and approx. 18 h 
incubation at 37°C with shaking (~140 RPM).
Refresh cultures were made by diluting an o/n culture 1:50 in the same medium 
and incubation at  37°C with shaking for approx.  2 h.  The optical  density of the 
culture was measured at the wavelength of 600 nm to ensure the mid-log phase of 
growth (OD600 range: 0.3-0.5). In calculations of culture cell density (CFU/ml), the 
obtained  value  was  referred  proportionally  to  that  of  a  standard  growth  curve 
determined before:
OD600 0.31 = 4.6 × 107 CFU/ml.
Isolated strains were prepared for storage at -80°C by adding 300 µl of 50% 
sterile glycerol solution in water to 500 µl of o/n culture.
2. Bacterial strains, plasmids and oligonucleotides
The list of E. coli strains, plasmids and PCR primers used in the discussed set 
of studies is presented in Table 3.
Table 3: Bacteria strains, plasmids and oligonucleotides used in the presented studies
Strains, plasmids 
and 
oligonucleotides
Characteristics or sequence Reference or source
E. coli strains
DH5α
HB101
BW25113
HCR1
HCR1C
JW3600
Plasmids
pBluescript II KS(+)
pMOSBlue
pBLR1
pBLR3
pBLR5
pBLR12
pBLR18
pBLR19
Wild type strain
Wild type strain
Wild type strain
E. coli HB101 waaY::Tn5 mutant
E. coli HCR1 carrying pKSM2 plasmid
E. coli BW25113 waaY::Kmr mutant
Cloning vector, Ampr
Cloning vector, Ampr
waaY::Tn5 cloned EcoRV in pBluescript KS+
ydbA::Tn5 cloned EcoRV in pBluescript KS+
waaY::Tn5 cloned EcoRV in pBluescript KS+
ynfF::Tn5 cloned EcoRV in pBluescript KS+
yohG::Tn5 cloned EcoRV in pBluescript KS+
gadB::Tn5 cloned EcoRV in pBluescript KS+
N/A
DSMZ
Genobase
This study
This study
Keio Collection
Stratagene
Amersham
This study
This study
This study
This study
This study
This study
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pBLR20
pKSM1
pKSM2
Oligonucleotides 
RFAY-VER-F
RFAY-VER-R
RFAY-F
RFAY-R
RFAZ-F
RFAZ-R
RFAK-F
RFAK-R
RFAPR-F
RFAPR-R
RFAYB-F
RFAYE-R
TN5-F
TN5-R
yhiU::Tn5 cloned EcoRV in pBluescript KS+
waaQ operon promoter cloned PstI-BamHI in pMOSBlue
waaY cloned BamHI-EcoRI in pKSM1
5'-CAGGAGTCTGTTATCTTTGCCG-3'
5'-TTTTGCGATGTAGGGCCCGAAA-3'
5'-ATGATTCAGAAGAGCAAGATCAAAG-3'
5'-TTAGCGCGCTGGTTTCCCTT-3'
5'-ATGAAGAATATTAGATACATTGACAAAAA-3'
5'-TTAATTAGCATAAGAATCGGTTGAAG-3'
5'-ATGCGCTTAGGAACTTTTCAC-3'
5'-TCACTTCTTATCTATACAACTTAATCT-3'
5'-ATCTGCAGCGGCCCCATTTTCAAATCTA-3'
5'-TTGGATCCCCCCATGATATCGCATCTTT-3'
5'-ATGGATCCATGATTCAGAAGAGCAAGATCAAAG-3'
5'-TAGAATTCTTAGCGCGCTGGTTTCCCTT-3'
5'- AAGGATCCGAGCCATATTCAACGGGAAA-3'
5'- AAAAGCTTGCCTGAGCGAGACGAAATAC-3'
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
N/A – not available
3. Mutant library production
3.1. Preparation of competent cells
To prepare competent cells of  E. coli HB101 strain, a standard o/n culture in 
LB broth was prepared and refreshed the following day in 200 ml of medium, up to 
an OD600 range of 0.5-0.7. The culture was transferred into four 50 ml tubes, cooled 
down on ice for 30 min and centrifuged at 1800 g, 4°C, for 15 min, and the medium 
was discarded. The remaining bacteria pellet was washed twice in 25 ml of sterile 
water  and  centrifuged,  and  the  supernatant  was  discarded.  The  cells  were 
resuspended in 10 ml of sterile 10% glycerol and centrifuged. Finally, the bacteria 
were resuspended in 1 ml of sterile 10% glycerol, distributed into several 1.5 ml 
tubes and stored at -80°C.
The rate of competence was verified with a test  transformation.  Fifty µl of 
freshly  thawed  competent  cell  suspension  were  mixed  with  1  µl  of  the  pUC18 
plasmid  solution  at  a  known  concentration,  transferred  into  an  electroporation 
cuvette, placed in the electroporator (MicroPulser, Biorad) and exposed to an electric 
discharge (1.8 kV, 5 ms).  Immediately afterwards,  950 µl  of  SOC medium were 
added and the cell suspension was incubated at 37°C for 1 h. Finally, the cells were 
diluted, plated on LB agar with ampicillin and the colonies were counted. The rate of 
competence  was  expressed  as  the  number  of  transformed  cells  per  1  µg  of  the 
plasmid and was considered sufficient at 108.
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3.2. Transformation with the transposon complex
Mutant cells derived from the HB101 strain were produced through a random 
insertion  of  Tn5  transposon  into  the  bacteria  genome.  Competent  cells  were 
electroporated  as  described  above  with  1  µl  of  EZ-Tn5™  <KAN-2>Tnp 
Transposome  solution  (Epicentre  Biotechnologies),  composed  of  a  transposase 
enzyme and the Tn5 transposon containing the Tn903 kanamycin resistance gene. 
The  transformants  were  plated  on  9  LB  agar  plates  (~100  µl/plate)  containing 
kanamycin  (25  µg/ml).  One  additional  plate  with  1:10  dilution  of  the  bacterial 
suspension was prepared to enable a proper colony count. The whole procedure was 
repeated 8 times and mutants from all the plates were collected, pooled, and several 
stocks were prepared for -80°C storage.
3.3. Extraction of genomic DNA of the mutants
Genomic DNA (gDNA) from 10 random mutant colonies, cultured o/n in 10 ml 
LB + 50 µg/ml kanamycin, was extracted using the sarkosyl-pronase lysis method 
(Birnboim,  1983).  Briefly,  the  cells  were  pelleted  and  resuspended  in  400 µl  of
1× TE buffer,  500 µl of 2% sarkosyl  in  1× TE and 100 µl pronase E (5 mg/ml, 
Sigma), and incubated at 37°C until the solution became clear. Then, 10 µl of RNase 
A (10 mg/ml, Sigma) were added and the incubation was continued for another 1 h. 
Afterwards, an equal volume of phenol/chloroform/isoamyl alcohol mix (25:24:1) 
was added, mixed thoroughly and centrifuged using a Biofuge Pico microcentrifuge 
(Heraeus) at 5,000 RPM for 5 min. The upper phase was collected and transferred 
into a new tube, and an equal volume of chloroform was added, followed by another 
centrifugation  and  transfer  of  the  upper  phase  into  a  new tube.  Subsequently,  a 
solution of 5 M NaCl was added to reach the final concentration of 0.2 M, which was 
followed by the addition of isopropanol (1:1). The precipitated DNA was transferred 
with a pipette tip into a tube containing 70% ethanol and centrifuged (13,000 RPM,
5  min).  The  supernatant  was  discarded  and  the  extracted  DNA was  dried  and 
resuspended  in  water.  The  concentration  and  purity  of  DNA  was  estimated 
spectrophotometrically by measuring the absorbance ratios at 230/260/280 nm.
Solutions and reagents
1× TE buffer: 10 mM Tris-HCl, 1.0 mM EDTA, pH 8.0.
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3.4. Confirmation of a random transposon insertion
To verify a correct and random insertion of Tn5 into the genome of HB101,
a Southern blot of digested and separated gDNA fragments was prepared.
3.4.1. Genomic DNA digestion
Four restriction enzymes with no cleavage sites inside the transposon sequence 
(EcoRI,  EcoRV,  NcoI,  KpnI)  were  tested  to  select  the  most  evenly  distributed 
digestion profile of gDNA. The digestions were carried out for 6 h at 37°C with the 
use of 40 µg of gDNA and 20 U of each enzyme (all from New England Biolabs). 
EcoRV was selected for further procedures.
3.4.2. Electrophoresis and transfer onto a membrane
The fragments of digested genome were separated through electrophoresis on 
0.8%  agarose  gel  (50  V,  3  h).  The  gel  was  then  photographed  on  a  UV 
transilluminator with a fluorescent ruler and subjected to three 30 min long washes: 
depurination, denaturation and neutralisation, performed in appropriate solutions (see 
below).
Subsequently, DNA fragments were transferred to an Amersham Hybond-N+ 
nylon membrane (GE Healthcare) in 20× SSC buffer. The transfer was set up as a 
“sandwich” composed of 4 layers of 3 mm chromatography paper (Whatman), the 
agarose  gel  facing  downwards,  the  nylon  membrane,  another  3  layers  of 
chromatography paper and ~100 layers of plain paper towel. After an approx. 18 h 
transfer, the membrane was incubated at 80°C for 2 h, for the purpose of fixing of the 
transferred DNA, and stored in a chromatography paper envelope at 4°C.
Solutions and reagents
Depurination solution: 0.13 M HCl;
Denaturation solution: 1.5 M NaCl, 0.5 M NaOH;
Neutralisation solution: 1.5 M NaCl, 0.5 M Tris-Cl, pH 7.5;
20× SSC buffer: 0.34 M trisodium citrate, 3 M NaCl.
3.4.3. Southern blot
The subsequent Southern blot assay was carried out using the DIG High Prime 
DNA Labeling  and  Detection  Starter  Kit  II  (Roche),  based  on  digoxigenin  and
AP-conjugated anti-DIG-antibody. A 467 bp long Tn5 fragment produced by PCR, 
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used as a probe, was labelled following the producer's indications and the labelling 
efficiency was then tested as described in the manual.
The following hybridisation procedure consisted of a 30 min pre-hybridisation 
of the membrane in DIG Easy Hyb solution (supplied with the kit) pre-heated to 
65°C, denaturation of the probe by boiling for 5 min, and its addition to the pre-
hybridisation solution. DNA was hybridised overnight in a closed glass container at 
65°C with constant agitation. Afterwards, the probe solution was removed, stored at 
-20°C and re-denatured  by boiling  before  every further  use.  The membrane  was 
subjected to two stringency washes, the first of which in 2× SSC, 0.1% SDS at room 
temperature for 2 × 5 min, and the second one in 0.5× SSC, 0.1% SDS at 65°C for
2 × 15 min, both with shaking.
To perform the immunological detection, the membrane was first incubated at 
room temperature (RT) for 5 min in washing buffer, washed for 30 min in blocking 
solution, incubated for 30 min with the secondary antibody solution, washed twice in 
washing buffer for 15 min and equilibrated in detection buffer for 5 min. Finally, the 
membrane was damped with the chemiluminescent substrate for alkaline phosphatase 
(CSPD, supplied with kit), wrapped in a plastic pellicle, incubated for 5 min at RT 
and exposed to a photographic film (X-OMAT LS, Kodak) in an exposition cassette 
(Hypercassette, Amersham) for approx. 30 min. The film was then processed using 
GBX developer and fixing solutions (Kodak).
Solutions and reagents
Washing buffer: 0.1 M maleic acid; 0.15 M NaCl, pH7.5; 0.3% (v/v) Tween 20;
Maleic acid buffer: 0.1 M maleic acid; 0.15 M NaCl; pH 7.5;
Blocking solution: 10× blocking solution (supplied) 1:10 in maleic acid buffer;
Secondary antibody solution: 75 mU/ml Anti-DIG-AP (supplied) in block. sol.;
Detection buffer: 0.1 M Tris-Cl; 0.1 M NaCl; pH 9.5.
4. Peptide preparation
4.1. Synthesis and purification
The peptides Bac7(1-16) and ppyLL-37 were generously supplied by the group 
of prof. Alessandro Tossi (University of Trieste).
LL-37 was synthesised on 2-chlorotrityl chloride-PS resin using the Fmoc/tBu 
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technology  of  Solid  Phase  Peptide  Synthesis  (SPPS)  on  a  Pioneer™  peptide 
synthesiser (PE Biosystems). The synthesised peptide was cleaved from the resin by 
incubation for 4 h on a shaker in the following mixture: 87% trifluoroacetic acid 
(TFA),  8%  3,6-dioxa-1,8-octane-dithiol  (DODT),  2%  triisopropylsilane  (TIPS),
3% water. The cleaved peptide was washed several times with tert-butyl methyl ether 
(TMBE) and dried with N2.
The purification was performed using an XTerra™ RP18 7 µm (19-300 mm) 
column attached to  a Gilson system of Reversed-Phase High-Performance Liquid 
Chromatography  (RP-HPLC)  managed  by  Unipoint  3.0  software.  The  applied 
gradient was set to reach 50% of acetonitrile in water from the initial 30% in 50 min. 
Subsequently,  the  collected  fractions  were  analysed  with  an  esquire6000™
mass-spectrometer  (Bruker  Daltonics)  and  those  of  high  purity  were  pooled  and 
lyophilised. In order to remove the possible TFA residues, the purified LL-37 was 
resuspended in 10 mM HCl and lyophilised once again, which was followed by the 
final resuspension in water.
4.2. Fluorescent labelling of LL-37
For the peptide-cell binding assay (see 12.), LL-37 was fluorescently labelled 
via  linkage of  the  thiol-reactive  fluorescent  dye  BODIPY® FL N-(2-aminoethyl) 
maleimide  (Invitrogen)  to  an  ad  hoc added  C-terminal  cysteine  residue.  Peptide 
labelling was carried out  in 10 mM sodium-phosphate buffer,  pH 7.4,  containing 
30% of  acetonitrile.  In  brief,  2  ml  of  a  1  mg/ml  solution  of  the  fluorescent  dye 
dissolved  in  acetonitrile  were  added  dropwise  to  18  ml  of  a  0.1  mg/ml  peptide 
solution under nitrogen bubbling.  After 2 h of incubation at  RT in the dark with 
stirring, a new aliquot of 2 mg of the peptide was added to the same solution and left 
overnight in the dark at 4°C with stirring. The excess of thiol-reactive reagent was 
then  scavenged  by  the  addition  of  10-fold  excess  of  cysteine.  After  30  min  of 
incubation at RT with stirring, the labelled peptide was purified using the procedures 
described above.
4.3. Peptide quantification
To  estimate  peptide  concentration,  the  Waddell  assay  was  used  (Waddell, 
1956). The analysis was conducted in a quartz cuvette (path length 10 mm; vol. 1 ml) 
by adding 2.5 µl of peptide solution to the blank (1 ml of 1/300 N NaOH), reading 
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OD at the wavelengths of 215 nm and 225 nm, subtracting OD225 from OD215 and 
multiplying the difference by the dilution factor (400). The addition of another 2.5 µl 
of peptide solution was followed by the same procedure (multiplier: 200) and the two 
results were then normalised and averaged. A previously synthesised antimicrobial 
peptide  ppyLL-37  was  used  as  a  reference.  Each  estimation  was  performed  in 
duplicate and averaged. The values calculated for the evaluated peptide were referred 
to those of the reference peptide with a known concentration, expressed in mg/ml.
5. Determination of the minimal inhibitory concentration
In order to determine the lowest peptide concentration that inhibits the growth 
of the tested strains (Minimal Inhibitory Concentration, MIC), the described standard 
o/n and refresh cultures  in  MH broth were set  up to  obtain mid-log phase cells, 
subsequently diluted to 5×105 CFU/ml. The accuracy of the dilution was verified by 
plating  50  µl  of  the  10-2 and  10-3 dilutions,  followed  by colony count  after  o/n 
incubation of the plates at 37°C.
The peptide was diluted serially in the wells of a microtiter plate in 50 µl of 
MH broth, and then 50 µl of previously prepared bacteria suspensions were added to 
the  wells,  thus  diluting  the  peptide  and  the  bacteria  to  half  of  their  initial 
concentrations in each well.  The whole plate was covered with a sterile adhesive 
plastic film to minimise the evaporation and incubated for 18 h at 37°C. The lowest 
peptide concentration that inhibited any visible growth of the bacteria was considered 
the MIC.
6. Selection of resistant mutants
To isolate the Tn5-mutants that potentially acquired resistance to Bac7(1-16) 
and LL-37, we chose a straightforward selection of the mutant library on solid media 
containing the peptide of interest. A cube of ~8 mm3 of frozen glycerol stock was 
suspended in 15 ml of MH or LB broth and incubated for ~4 h at 37°C with shaking.
Plates with 15 ml of MH agar were prepared with the desired quantities of
LL-37 dissolved in the medium while still liquid, and the final concentrations of 1, 5, 
10, 20 and 30 µM LL-37 were obtained. Bac7(1-16) was incorporated into LB agar 
at the final concentration of 5 µM.
Bacteria cultures were diluted in their  respective liquid media to obtain the 
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density of 106 CFU/ml and 100 µl of the diluted cultures were spread over the agar 
plates enriched with the appropriate peptide, resulting in the final number of approx. 
105 cells per plate. Among the colonies that grew on the plates, only the ones with no 
background (small, closely surrounding colonies) were chosen and re-plated on LB 
agar with kanamycin. Glycerol stocks of each mutant clone were prepared from these 
plates and stored at -80°C.
The  mutants  that  survived  the  selection  with  Bac7(1-16)  were  named  B7R 
(Bac7-Resistant) and numbered consecutively.
To verify the results of the selection with LL-37, selected strains were tested 
for resistance on a microtiter plate in 50 µl of MH broth with the addition of 5 µM 
LL-37, along with the wild-type strain as a reference. The bacteria were inoculated 
from previously prepared plates of LB agar with kanamycin, using the tip of a sterile 
toothpick.  The verification  was considered  valid  when the strain  growth after  an 
overnight incubation was clearly visible. The strains that passed the verification were 
named HCR (Human Cathelicidin-Resistant) and numbered consecutively.
7. Identification of the mutated genes in B7R mutants
Identification  of  mutation  sites  was  carried  out  by cloning  of  the  genomic 
fragments  containing  Tn5  from  the  isolated  resistant  clones  (B7R1-11),  and 
subsequent sequencing of the cloned gDNA fragments surrounding the transposon.
7.1. Preparation of the cloning vector
The plasmid pBluescript II KS+ was extracted from previously transformed
E. coli HB101 using the illustra™ plasmidPrep Mini Spin Kit (GE Healthcare) and 
quantified spectrophotometrically.
Approx. 12 µg of the plasmidic DNA was digested with 20 U of EcoRV (New 
England Biolabs) for 6 h at 37°C. The whole digestion mix was then loaded onto a 
0.8% agarose gel and separated by electrophoresis (3 h, 50 V, 10-20 mA), in parallel 
with  a  MW  marker  (SharpMass  1  kb  DNA ladder,  EuroClone).  The  gel  band 
containing  the  linearised  plasmid  was  excised  and  the  DNA was  eluted  using 
GenElute™ Gel Extraction Kit (Sigma). As the digestion produced blunt ends, the 
linear pBluescript II KS+ was subjected to a two-step dephosphorylation, with 20 U 
of Calf  Intestinal  Phosphatase (CIP,  New England Biolabs)  initially added to the 
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reaction mix and 10 U of CIP added after 2 h at 37°C for another 1 h of incubation. 
Finally, the prepared vector was purified using QuickClean 5M PCR Purification Kit 
(GenScript Corp.).
7.2. Construction of genomic libraries of the mutants
The following step was ligation of the vector with the genomic fragments of 
the mutant clones, obtained by extracting and digesting gDNA (see 3.3. and 3.4.1.). 
The ligation was conducted in the total  vol.  of 15 µl using 10× T4 ligase buffer 
(containing 600 µM ATP) and 10 U of T4 ligase (USB). The quantity of the vector 
(~100 ng) and the gDNA fragments used were set to obtain the molar ratio of 1:5,  
respectively.  The calculation of molarity of the insert  was based on an estimated 
medium size of the gDNA fragments produced by EcoRV. The mix was incubated for 
18 h at 16°C.
7.3. Screening of the libraries and insert sequencing
Four µl of each ligation mix were used to transform  E. coli DH5α cells by 
electroporation (see 3.1.). The transformants were plated on LB agar with ampicillin 
and 50 µg/ml kanamycin, so as to allow the growth of only those cells that assumed 
the plasmid containing  gDNA fragment  that  carried Tn5 with its  Kmr gene.  The 
extracted plasmids were sequenced (BMR Genomics, Padova, Italy) using KAN-2 
FP-1 and RP-1 primers (supplied with EZ-Tn5™ kit) that allowed the sequencing of 
the regions located outside the transposon, which indicated the interrupted genes. 
The  obtained  sequences  were  analysed  with  BLAST  (Altschul  et  al.,  1997) and 
elaborated with BioEdit software (Hall, 1999) to precisely determine the location of 
Tn5 in the mutant genomes.
8. Identification of the mutated genes in HCR mutants
8.1. Preliminary identification
To perform a preliminary identification of the mutants, the isolated resistant 
clones (HCR1-20) were cultured, their gDNA was extracted, digested with EcoRV 
restriction enzyme and Southern-blotted using the previously described procedures 
(see 3.4.).
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8.2. Determination of mutation sites in 6 mutants
Identification  of  mutation  sites  was  performed  by  cloning  of  the  genomic 
fragments  containing  Tn5  from  7  mutant  clones,  that  presented  different 
hybridisation profiles, into pBluescript II KS+, followed by the sequencing of the 
inserts,  as  described  in  Paragraph  7. The  sequenced  plasmids  containing  the 
fragments that carried Tn5 were named pBLR1, 3, 5, 12, 18, 19 and 20, according to 
their respective clone numbers (Tab. 3).
8.3. PCR identification of the remaining mutants
In the mutant clones that were not sequenced, the transposon insertion was 
revealed by PCR amplification of the waaY (rfaY) gene, interrupted in the sequenced 
mutant presenting the most prevalent hybridisation profile.
Reaction mix (50 µl) was composed of:
• 10 µl of 5× GoTaq buffer (“Green”, containing electrophoresis loading buffer);
• 4 µl of 25 mM MgCl2;
• 0.5 µl of GoTaq DNA polymerase (all three from Promega);
• 1 µl of 10 mM dNTPs;
• 5 µl of each of 5 µM primers: RFAY-VER-F and RFAY-VER-R;
• 2 µl of gDNA template (0.5-1 µg);
• water to volume.
The amplification was carried out on a EuroClone One Advanced thermocycler 
using the following programme: pre-denaturation (94°C, 5 min),  35 amplification 
cycles (94°C, 1 min; 55°C, 1 min; 72°C, 2 min), final elongation (72°C, 5 min). The 
products  were separated by electrophoresis  on 0.8% agarose gel  (50 V, 1 h) and 
visualised on a UV transilluminator.
9. RT-PCR analysis
E.  coli HB101 and  HCR1 strains  were  cultured  until  an  OD600 of  0.4  was 
reached. Total RNA was extracted from bacterial cells, lysed by several freeze/thaw 
cycles,  using the TRIzol Plus RNA Purification Kit  (Invitrogen) and any residual 
genomic DNA was removed by RQ1 RNase-Free DNase (Promega) (1 U per 1 µg of 
RNA).
cDNA was synthesised from approx. 1 µg of isolated RNA, using 0.5 µg of 
random hexamer  primers  (Promega)  and 200 U of  M-MLV reverse  transcriptase 
(USB), in the presence of 40 U of RNasin Plus RNase Inhibitor (Promega). The 1 h 
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long reaction was conducted at 42°C.
PCR  based  on  the  cDNA template  was  performed  using  RFAY-F/RFAY-R 
primers to amplify the waaY (rfaY) gene, RFAZ-F/RFAZ-R primers to amplify waaZ 
(rfaZ),  and  RFAK-F/RFAK-R  primers  to  amplify  waaU (rfaK) (Tab.  3),  in  the 
following reaction mix:
• 10 µl of 5× GoTaq buffer;
• 1 µl of 100 mM MgSO4;
• 0.5 µl of GoTaq DNA polymerase;
• 1 µl of 10 mM dNTPs;
• 0.5 µl of each of 100 µM primer pairs;
• 6 µl of cDNA template;
• water to volume.
The  amplification  programme  was  composed  of:  pre-denaturation  (94°C,
5 min), 30 amplification cycles (94°C, 30 s; 55°C, 40 s; 72°C, 40 s) and the final 
elongation  (72°C,  7  min).  The  products  were  separated  electrophoretically  and 
visualised on a UV transilluminator.
10. Trans-complementation of the waaY mutation
To complement the waaY mutation, the HCR1 mutant strain was transformed 
with the pKSM2 plasmid, based on pMOSBlue, carrying a functional copy of waaY 
downstream of waaQ operon promoter (Tab. 3).
The waaY gene was amplified from E. coli HB101 gDNA using RFAYB-F and 
RFAYE-R  primers,  that  added  BamHI-EcoRI  restriction  sites  to  the  amplified 
fragment, in the following reaction mix:
• 10 µl of 5× GoTaq buffer;
• 1 µl of 100 mM MgSO4;
• 0.5 µl of Vent DNA polymerase;
• 2 µl of 10 mM dNTPs;
• 1 µl of each of 100 µM primers;
• 1 µl of gDNA template (approx. 500 ng);
• water to volume,
using  the  following  PCR  programme:  pre-denaturation  (94°C,  5  min),  30 
amplification cycles (94°C, 30 s; 58°C, 40 s; 72°C, 40 s), final elongation (72°C,
7 min). The product was digested with EcoRI and BamHI to create sticky ends and 
ligated  with  pMOSBlue  linearised  with  the  same  pair  of  enzymes,  creating  the 
pKSM1 plasmid.
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The waaQ operon promoter (Clementz, 1992) was then amplified from HB101 
gDNA using RFAPR-F and RFAPR-R primers, that added PstI-BamHI restriction 
sites  to  the  amplified  fragment,  in  a  reaction  mix  as  shown  above,  using  the 
following PCR programme: pre-denaturation (94°C, 5 min), 30 amplification cycles 
(94°C, 30 s; 60°C, 30 s; 72°C, 30 s), final elongation (72°C, 7 min). The product was 
digested  with  PstI  and  BamHI,  to  create  sticky  ends,  and  ligated  with  pKSM1 
linearised with the same pair of enzymes, creating the pKSM2 plasmid, which was 
eventually sequenced to ensure the correctness of the construct.
pKSM2, containing the waaQ promoter and the waaY gene between PstI and 
EcoRI restriction sites,  was then used for the transformation of competent HCR1 
cells by electroporation (see 3.1.).
11. Antimicrobial activity assays
11.1. Growth kinetics assay
To determine the growth inhibition of the bacteria exposed to various peptide 
concentrations,  we  chose  an  OD-based  approach  of  measuring  the  cell  density 
changes over the incubation time on a microtiter plate.
Mid-log  phase  bacteria  cultures  were  diluted  in  MH  broth  to
2  × 106 CFU/ml  and  100  µl  of  each  dilution  were  added  to  100  µl  of  peptide 
solutions, previously prepared on a microtiter plate, or to 100 µl of medium with no 
peptide, as a control. Thus prepared solutions of 106 CFU/ml, with the peptide at half 
of  the  original  concentration,  were  placed  inside  a  plate  reader  (Tecan  Sunrise, 
Switzerland) and incubated at 37°C throughout the assay with intermittent shaking. 
The OD change was measured at the wavelength of 620 nm with 10-minute intervals 
for 4 h (25 cycles).  The data from the experiments,  performed in triplicate,  were 
collected by Magellan 4 software (Tecan) and averaged.
11.2. Killing kinetics assay
The  effective  killing  rate  of  LL-37  was  expressed  by the  reduction  of  the 
number of CFU after a 90 min incubation with 2 µM peptide.
Mid-log  phase  bacteria  cultures  were  diluted  in  MH  broth  to
2  × 106 CFU/ml, and 200 µl of the dilutions were added to 200 µl of previously 
prepared 4 µM peptide solution and to  200 µl  of medium with no peptide,  as a 
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control. Thus prepared solutions of 106 CFU/ml without the peptide and with 2 µM 
LL-37  were  incubated  at  37°C  for  90  min  with  shaking.  The  initial  bacteria 
suspensions were serially diluted, and 50 µl of 10-3 and 10-4 dilutions were plated in 
duplicate on MH agar.
After the 90 min incubation, bacteria suspensions were immediately diluted in 
high-salt PBS. Fifty µl of 100 through 10-2 dilutions of the peptide-treated bacteria 
and 50 µl of 10-3 and 10-4 dilutions of the untreated bacteria were plated in duplicate 
on MH agar. The obtained data, expressed in CFU/ml, were averaged within each 
duplicate.  Significance  of  the  results  was  evaluated  with  the  unpaired  t-test, 
performed  using  GraphPad QuickCalcs software,  and the  values  of  P<0.05 were 
considered statistically significant.
12. Flow cytometry assays
Binding of BODIPY-labelled LL-37 to  E. coli cells was determined by flow 
cytometry using a Cytomics FC 500 instrument (Beckman-Coulter, Inc.) equipped 
with an argon laser (488 nm, 5 mW) and a photomultiplier tube fluorescence detector 
for  green  (525 nm)  or  red  (610 nm)  filtered  light.  All  detectors  were  set  to  the 
logarithmic amplification. Optical and electronic noise were eliminated by setting the 
electronic gating threshold on the forward-scattering detector, while the data flow 
rate was kept below 300 events per second to avoid cell coincidence. At least 10,000 
events were acquired for each sample.
Cultures of mid-log phase bacteria were harvested, brought to 106 CFU/ml in a 
diluted medium (20% MH broth in sodium phosphate buffer), incubated with 0.1 μM 
and 0.25 μM LL-37-BODIPY® at 37°C for 10 min and analysed immediately. All 
experiments  were  conducted  in  triplicates  and  the  data  were  expressed  as  Mean 
Fluorescence Intensity (MFI) ± S.D.  Significance of the results was evaluated with 
the unpaired t-test, performed using GraphPad QuickCalcs software, and the values 
of P<0.05 were considered statistically significant.
Permeabilisation of the cytoplasmic membrane of E. coli was assessed by flow 
cytometry, measuring the uptake of propidium iodide (PI) into dividing cells, diluted 
to 106 CFU/ml. Fluorescence of the internalised PI was measured after 15, 30, 45 and 
60 min of cell incubation with 0.25  μM and 0.5 μM LL-37 at 37°C, as previously 
described (Podda et al., 2006). Permeabilisation data were expressed as a percentage 
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of PI-positive cells. Data analysis was performed with the FCS Express V3 software 
(De Novo Software, CA).
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1. Mutant library production and verification
1.1. Estimated number of clones
E. coli random knock-out mutant library was prepared by transformation of 
HB101  strain  cells  with  a  commercially  available  Tn5  transposon-transposase 
complex  and  selection  of  the  transformants  on  a  solid  medium  containing 
kanamycin.
Colony count on the plates with transformant suspension dilutions, prepared 
for this purpose, allowed us to estimate the total number of separate clones obtained 
from 9 transformations as approx. 59,000. All the colonies were collected from the 
plates, pooled and stored in several stock tubes.
1.2. Selection of the restriction enzyme to digest mutant gDNA
Four restriction enzymes that do not have cleavage sites within the sequence of 
the  Tn5  transposon  were  tested  for  their  digestion  profiles  of  genomic  DNA of
E. coli HB101. The digestion profile presenting the most evenly distributed fragment 
lengths was produced by EcoRV (Fig. 8), which was used in further procedures.
1.3. Verification of the random insertion of Tn5
A Southern  blot  analysis  was  performed  to  verify  the  randomness  of  Tn5 
insertion by hybridisation of a Tn5 probe with the genomes of 20 randomly selected 
mutant clones digested with EcoRV and separated electrophoretically. The results of 
this analysis for 10 clones out of 20 are presented in Figure 9.
63/111
Figure 8: Test digestion of the genome of E. coli HB101 
with four restriction enzymes not cutting inside the Tn5 
transposon. The black frame marks the enzyme EcoRV 
chosen for further procedures because it generated the 
most evenly distributed fragment lengths.
EcoRI EcoRV NcoI KpnI
RESULTS
Almost  all  of  the  randomly  chosen  Tn5  mutants  presented  different 
hybridisation profiles with the Tn5 probe, suggesting that the transposon insertion 
was random. According to the producer of the kit, the insertions are also unique per 
genome, so the presence of an additional weak hybridisation signal at 3.3 Kb in clone 
8 can be explained either with an aspecific digestion of the genome by EcoRV or 
with an aspecific annealing of the probe.
2. Selection, identification and characterisation of Bac7(1-16)-resistant mutants
2.1. Selection and identification of the resistant clones
The  Tn5  mutant  library  was  subjected  to  a  selection  on  a  solid  medium 
containing  Bac(1-16), by plating 105 CFU on an LB agar plate supplemented with
5 µM peptide, which led to the selection of 11 resistant clones, named B7R1 through 
B7R11.
Genomic DNA of the B7R mutants was extracted and digested with EcoRV. 
This was followed by the ligation of genomic fragments with the pBluescript II KS+ 
cloning vector. E. coli DH5α cells were then transformed with the ligation products 
and plated on LB agar with ampicillin and kanamycin to select only the cells that 
carried  the  plasmid  containing  gDNA fragment  with  Tn5  insertion.  One  to  two 
colonies per clone were amplified and the plasmids were extracted and sequenced 
using KAN-2 FP-1 and RP-1 primers,  which revealed the sequence of the genes 
interrupted by Tn5. The name and function of the inactivated genes and Tn5 position 
in each B7R clone are presented in Table 4.
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Figure 9: Southern blot analysis of digested gDNA of the mutants hybridised with the Tn5 probe. The 
numbers 1-10 represent ten randomly chosen clones.  The numbers  above the bands represent the 
estimated  fragment  lengths  in  kilobases  (Kb),  according  to  the  molecular  weight  markers.  The 
analysis confirmed that Tn5 transposon insertion into the genome of HB101 was random.
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RESULTS
Table  4:  List of the mutant clones selected on Bac7(1-16)-enriched medium and description of the 
interrupted genes.
Mutant Mutated gene
Tn5 
position Function of the mutated gene Reference
B7R1 yehY 592-600 Putative membrane component of an uncharacterised ABC transporter
(Checroun and Gutierrez, 
2004; Saurin et al., 1999)
B7R2 yjhT (nanM) 434-442
Subunit of N-acetylneuraminate 
mutarotase
(Condemine et al., 2005; 
Severi et al., 2008)
B7R3-5, 
7-10 sbmA various
Transmembrane domain of a 
putative ABC transporter, facilitates 
the uptake of some AMPs
(Mattiuzzo et al., 2007; 
Salomón and Farías, 1995)
B7R6 intergenic region -
Tn5 is located in a short palindrome 
sequence (box C) between the phnP 
gene (encoding a C-P lyase complex 
accessory protein) and the yjdP gene 
(encoding a hypothetical protein)
(Metcalf and Wanner, 1991; 
Yakovleva et al., 1998)
Ecocyc: G0-9541
B7R11 waaP 410-419 Kinase of heptose I of LPS inner core, part of the waaQ operon
(Yethon and Whitfield, 2001; 
Yethon et al., 1998)
The  exact  Tn5  position  was  determined  by  aligning  the  obtained  sequences  with  E.coli gene 
sequences from Colibri website (http://genolist.pasteur.fr/Colibri/) in BioEdit (Hall, 1999).
2.2. Growth kinetics of 5 different clones
A brief characterisation of growth inhibition of 5 different B7R mutants by 
Bac7(1-16) was performed by conducting a growth kinetics assay, using 0.5 and 1 
µM peptide in MH broth and a control with no Bac7(1-16) added.
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Figure 10: Growth kinetics of the analysed B7R mutants in MH broth with no peptide (A) and with
0.5 µM (B) and 1 µM (C) Bac7(1-16). The experiment demonstrated a higher growth of B7R3 and 
B7R6 cultures in the presence of Bac7(1-16) at both concentrations applied, compared to the wild type 
and to other tested mutant clones. Representative of at least three independent experiments.
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RESULTS
Some differences in cell fitness were observed in the medium not containing 
Bac7(1-16). The mutants B7R3, 6 and, most of all, 11 presented a lower growth rate 
compared to other two mutants and to the wild type (Fig. 10A). However, incubation 
of B7Rs with 0.5 µM Bac7, resulting in a general growth reduction, showed a 2-fold 
growth advantage of B7R3 and B7R6 cultures over other tested strains (Fig. 10B). In 
the medium with 1 µM peptide the difference got reduced to approx. 1.5-fold but still 
remained visible (Fig. 10C).
3. Selection, identification and characterisation of LL-37-resistant mutants
3.1. Selection and isolation of mutant clones resistant to LL-37
Tn5 mutant library was subjected to a selection on a solid medium containing 
LL-37, by plating 105 CFU on MH agar plates with incorporated 1, 5, 10, 20 and
30 µM peptide.
On  the  plates  containing  ≤  20  µM of  the  human  cathelicidin  a  growth  of 
thousands of colonies was observed, suggesting an insufficient level of selection, and 
those plates were disregarded.
On the plate containing 30 µM peptide, 20 resistant clones were obtained and 
named HCR1 through HCR20. They were tested for the resistance in MH broth with 
5 µM LL-37.
3.2. Analysis of the hybridisation profiles of the twenty isolated clones
Genomic  DNA of  the  HCR1-20  mutants  was  extracted  and  digested  with 
EcoRV. A Southern blot of the digested genomes was then performed using the Tn5 
probe.  The  assay  revealed  6  different  hybridisation  profiles,  one  of  which  was 
present in 15 out of 20 selected clones (Fig. 11).
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3.3. Each hybridisation profile corresponded to a different interrupted gene
Genomic fragments of the mutants HCR1 and 5,  representing the prevalent 
hybridisation profile, and HCR3, 12, 18, 19 and 20, representing other hybridisation 
profiles, were ligated with the pBluescript II KS+ cloning vector. E. coli DH5α cells 
were  then  transformed  with  the  ligation  products  and  plated  on  LB  agar  with 
ampicillin and  kanamycin  to  select  only  those  cells  that  carried  the  plasmids 
containing gDNA fragments with Tn5 insertion. One to two colonies per clone were 
subcultured, and the plasmids were extracted and sequenced using KAN-2 FP-1 and 
RP-1 primers, which revealed the genes interrupted by Tn5. The name and function 
of the inactivated genes and genomic position of Tn5 in the analysed HCR mutants 
are presented in Table 5.
Table 5: List of the sequenced mutant clones selected on LL-37-enriched medium and description of 
the interrupted genes.
Mutant Mutated gene Tn5 position Function of the mutated gene Reference
HCR1
waaY (rfaY)
393-401 Kinase of heptose II of LPS inner 
core, part of the waaQ operon (Yethon et al., 1998)HCR5 177-185
HCR3 ydbA 3128-3136
A pseudogene interrupted by two 
independent insertions, IS30C and 
IS2D
EcoGene Acc.No.
EG11307
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Figure 11: Southern blot of digested gDNA of the HCR1-20 mutants hybridised with the Tn5 probe.  
From the 6 different profiles observed, one was particularly prevalent and present in 15 clones.
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HCR12 ynfF 222-230
Oxidoreductase subunit of a 
putative selenate reductase, 
reducing selenates to elemental Se
(Guymer et al., 2009)
HCR18 mdtQ (yohG) 818-826
An outer membrane factor (OMF) 
family component of a multidrug 
efflux system
(Sulavik et al., 2001)
HCR19 gadB 185-193
A glutamate decarboxylase of the 
glutamate-dependent acid resistance 
system 2 conferring resistance to 
extreme acid conditions
(Gut et al., 2006)
HCR20 mdtE (yhiU) 342-350
A homotrimer assembling with 
trimeric MdtF and TolC to form an 
efflux pump in the inner membrane
(Nishino and Yamaguchi, 
2002)
The  exact  Tn5  position  was  determined  by  aligning  the  obtained  sequences  with  E.coli gene 
sequences from Colibri website (http://genolist.pasteur.fr/Colibri/) in BioEdit (Hall, 1999).
3.4. Confirmation of waaY interruption in the other selected clones
The remaining 13 resistant clones presenting the prevalent hybridisation profile 
were  identified  by PCR amplification  of  the  waaY gene,  that  was  interrupted  in 
HCR1. Product sizes were then compared to the size of the wild-type waaY, present 
in  HCR12,  18,  19,  and  20  (Fig.  12).  The  procedure  confirmed  that  the  mutants 
presenting similar results of the Southern blot assay also shared the mutation site, 
located in the waaY gene.
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Figure 12: PCR analysis of Tn5 transposon insertions into the waaY gene of the HCR2 and HCR4-20 
mutants. The arrows indicate theoretical product sizes with (waaY + Tn5) and without (waaY) the 
insertion.
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3.5. Growth kinetics of 6 different clones
To estimate the growth inhibition of  6  different  HCR mutants by LL-37,  a 
growth kinetics assay was carried out using 1 and 2 µM peptide in MH broth and a  
control with no LL-37 added.
Cell fitness in the medium with no peptide was equal except for HCR1 that 
presented  an  approx.  20%  slower  growth  kinetics  (Fig.  13A).  Surprisingly, 
incubation of HCRs with 1 µM LL-37 completely abolished the growth of all strains 
but HCR1, that presented only a 60% reduction compared to the control (Fig. 13B). 
From the two strains tested in the medium with 2  µM peptide, HB101 and HCR1, 
none of them managed to grow detectably (Fig. 13C).
Since some grade of decreased susceptibility to LL-37 was detected only in 
HCR1, and its waaY-knock-out mutation was present in 15 out of 20 selected clones, 
we  decided  to  confirm  that  this  mutation  was  the  only  cause  of  the  observed 
phenotype  and  to  further  characterise  its  resistance  to  and  interactions  with  the 
peptide.
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Figure  13:  Growth  kinetics  of  6  HCR  mutants  in  MH  broth  with  no  peptide  (A)  and  with
1 µM (B) and 2 µM (C) LL-37. Only HCR1 managed to grow in the presence of 1 µM LL-37, and
2  µM  peptide  inhibited  completely  the  growth  of  all  strains  under  the  conditions  applied. 
Representative of at least three independent experiments.
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RESULTS
3.6. The second selection and characterisation of 8 of 24 new resistant clones
Tn5 mutant library was subjected to a second selection on a solid  medium 
containing 30 µM LL-37, which led to the isolation of 24 resistant clones, that were 
immediately tested  for the presence of Tn5 insertion inside the  waaY gene using 
PCR. Sixteen out of 24 isolated clones showed a positive result and were discarded. 
The remaining 8 mutants, with an unknown Tn5 localisation, were named HCR21 
through 28 and preserved.
Resistance to  growth inhibition by LL-37 in the newly selected clones was 
characterised with a growth kinetics assay, whose results are presented in Figure 14.
With 1 µM LL-37, HCR22 and 28 grew similarly to HCR1 from the previous 
experiment (60% reduction, see Fig.  13B), and three other clones, HCR23, 26 and 
27, managed to obtain 25% of the control culture density. Other mutants and the wild 
type were completely inhibited under these conditions (Fig.  14B). Two µM peptide 
abolished completely the growth of all strains (Fig. 14C).
Mutation sites in the HCR21-28 mutant clones are now to be identified using 
the same procedures that led to the identification of HCR1-20.
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Figure  14: Growth kinetics of the HCR21-28 mutants in MH broth with no peptide (A) and with
1 µM (B) and 2 µM (C) LL-37. HCR22 and 28 presented a 60% growth reduction, and HCR23, 26 
and 27 showed a 75% growth reduction compared to the control incubation, whereas other strains 
were inhibited completely. None of the strains managed to grow in the presence of 2  µM peptide. 
Representative of at least three independent experiments.
0 60 120 180 240
0,0
0,1
0,2
0,3
No LL-37
HB101
HCR21
HCR22
HCR23
HCR24
HCR25
HCR26
HCR27
HCR28
time [min.]
O
D
 @
 6
20
 n
m
A
0 60 120 180 240
0,0
0,1
0,2
0,3
1 µM LL-37
time [min.]
O
D
 @
 6
20
 n
m
B
0 60 120 180 240
0,0
0,1
0,2
0,3
2 µM LL-37
time [min.]
O
D
 @
 6
20
 n
m
C
RESULTS
3.7. Significance of the prevalence of waaY-mutants
A PCR amplification of the  waaY gene was performed in  27 random clones 
from the Tn5 mutant library. None of the electrophoretically separated PCR products 
carried the Tn5 insertion, as the size of all products was equal to that of the wild-type 
gene. This confirmed that the prevalence of waaY-mutants isolated in both selections 
with LL-37 (75% and 67% of all selected clones in the first and the second selection, 
respectively)  was not  a  result  of coincidence or preferential  transposon insertion. 
Different  Tn5  positions  in  the  two  sequenced  waaY mutants,  HCR1 and  HCR5, 
support this assumption.
4. Resistance in HCR1 was caused by the inactivation of waaY
4.1. The downstream genes were not inhibited by Tn5 insertion
waaY  (rfaY) is  the  third-to-last  gene  of  the  waaQ (rfaQ) operon (Fig.  15). 
Although there is a putative promoter sequence before the two downstream genes, 
waaZ (rfaZ) and waaU, it seemed correct to verify the possibility of inactivation of 
those genes by Tn5 insertion. For this purpose, an RT-PCR analysis of all three genes 
was conducted in both HB101 and HCR1.
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Figure 15: The waaQ (rfaQ) operon and its local genetic context. Two previously known promoters (rfaQp1 and 2) and a recently discovered one [rfaYp (Lee et  
al., 2009)] are marked by continuous arrows. A putative promoter (rfaZp) is marked by a dashed arrow. (Ecocyc)
RESULTS
The results of RT-PCR, presented in Figure 16, confirmed that the insertion of 
Tn5 into the genome of HCR1 inactivated only the waaY gene and did not inhibit the 
expression of  waaZ and  waaU. Complementary DNA fragments of the two latter 
genes, produced on the template of total RNA extracted from HCR1, were present 
and appeared in a quantity similar to that of the wild type.
4.2. Trans-complementation  of  the  mutation  restored  the  wild-type 
phenotype
To complement the waaY mutation, the HCR1 mutant strain was transformed 
with the pKSM2 plasmid carrying a functional copy of the waaY gene downstream of 
the waaQ operon promoter, constructed from the pMOSBlue cloning vector and both 
genomic fragments cloned separately.
Full restoration of the wild-type phenotype in the transformant named HCR1C 
was verified in a growth kinetics assay, whose results are presented in Figure 17. For 
this test,  the strains HB101 and HCR1 were first transformed with pMOSBlue to 
exclude any possible influence of the plasmid and ampicillin in the medium.
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Figure 16: RT-PCR analysis of the waaYZU gene expression in HB101 (wild type) 
and HCR1 (waaY-knock-out). The lack of cDNA of HCR1 waaY gene indicates that 
it  is  not  expressed in this mutant,  whereas the expression of  waaZ and  waaU is 
unaffected by transposon insertion.
Figure 17: Growth kinetics of the complemented waaY-knock-out strain (HCR1C) in MH broth with 
no peptide (A) and with 1 µM LL-37 (B). Equal level of growth inhibition by the peptide observed in 
HB101 and HCR1C proves a full restoration of the wild-type phenotype in the complemented HCR1. 
Representative of at least three independent experiments.
MW waaY waaZ waaU waaY waaZ waaU
1000
750
500
HB101 HCR1
bp
0 60 120 180 240
0,0
0,1
0,2
0,3
No LL-37
time [min.]
O
D
 @
 6
20
 n
m
0 60 120 180 240
0,0
0,1
0,2
0,3
1 µM LL-37
HB101
HCR1
HCR1C
time [min.]
O
D
 @
 6
20
 n
m
A B
RESULTS
Even though the tested strains showed some differences in the growth rate in a 
medium with no peptide (Fig.  17A), the addition of 1  µM LL-37 inhibited equally 
the growth of HB101 and HCR1C cultures, while permitting a growth rate of HCR1 
(Fig.  17B) similar to that observed in the previous test (see Fig.  13B). The results 
confirmed that the plasmid carrying waaY with its promoter restored the susceptible 
phenotype of HB101 in the waaY-knock-out mutant.
4.3. HCR1 was killed less efficiently by LL-37 than HB101 and HCR1C
The peptide's effective killing rate of the mutant, complemented and wild-type 
strains  was expressed as  the reduction of  the number of  CFU/ml after  a  90 min 
incubation with 2 µM LL-37, in parallel with control samples with no peptide added.
The  results  are  an  average  of  three  independent  experiments  and  show an 
approx. 1 log CFU reduction of the peptide-treated HCR1, whereas the CFUs of 
HB101 and HCR1C were reduced by 3-4 logarithms (Fig. 18). The control samples 
of untreated bacteria increased their CFU number approx. 10 times, with a slightly 
slower growth of HCR1, as seen in the growth kinetics assay (see Fig.  13A). This 
way,  both  the  decreased  susceptibility  of  the  waaY mutant  to  LL-37  and  the 
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Figure 18: Killing kinetics assay of HB101, HCR1 and HCR1C. The reduction of CFU/ml from the 
initial 106 was examined after 90 min of incubation with 2 µM LL-37, in parallel with control samples 
with no peptide added. The results confirmed both the decreased susceptibility of HCR1 to LL-37 and 
the restoration of the wild-type susceptibility in HCR1C. However, according to the unpaired  t-test 
performed between the treated strains, the results were not statistically significant using the threshold 
P value of 0.05.
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RESULTS
restoration  of  the  wild-type  susceptibility  in  the  complemented  mutant  were 
confirmed.  However,  although  in  each  of  the  three  experiments  performed  the 
difference between HCR1 and HB101, and HCR1 and HCR1C was clearly evident, 
the significance was not achieved due to the wide scatter of the data from experiment 
to experiment.
5. LL-37 bound and permeabilised HCR1 cells with lower efficiency
Binding of LL-37 to the mutant, complemented and wild-type strain cells was 
determined  by flow cytometry  after  incubation  of  the  cultures  with  0.1  μM and
0.25 μM LL-37-BODIPY® at 37°C for 10 min.
The data, expressed as Mean Fluorescence Intensity (MFI) ± S.D., showed that 
HCR1  bound  at  least  2  times  less  peptide  than  HB101  and  HCR1C  (Fig.  19), 
suggesting that the mutation decreased the attraction of LL-37 by the mutant cells. 
Fluorescence of the cells incubated with 0.1 μM LL-37 was roughly two times lower 
than  that  of  the  cells  incubated  with  0.25  μM  peptide,  apparently  because  the 
peptide-binding  capability  of  the  cells  that  was  not  saturated  at  the  lower 
concentration.
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Figure 19: Flow cytometry assay of binding of fluorescently labelled 0.1 µM and 0.25 µM LL-37 by 
HB101, HCR1 and HCR1C cells,  expressed as Mean Fluorescence Intensity (MFI).  HCR1 bound 
approx. 2 times less peptide than HB101 and HCR1C and there was an approx. 2-fold difference in 
the fluorescence level between the two peptide concentrations applied. Asterisks mark the results that 
were statistically significant compared to the results of HCR1 with 0.1 µM LL-37 (*) and 0.25 µM 
LL-37 (**), according to the unpaired t-test . P values obtained with 0.1 µM LL-37: 0.0002 (HB101 
vs.  HCR1),  <0.0001 (HCR1C vs.  HCR1),  and with 0.25  µM LL-37:  0.0062 (HB101 vs.  HCR1), 
0.0093 (HCR1C vs. HCR1).
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Permeabilisation  of  the  cytoplasmic  membrane  by  LL-37  was  assessed  by 
measuring the uptake of propidium iodide (PI) by HB101 and HCR1 cells after 15, 
30, 45 and 60 min of incubation with 0.25 μM and 0.5 μM peptide.
Permeabilisation  data,  expressed  as  a  percentage  of  PI-positive  cells  and 
presented in  Figure 20, showed that there was an approx. 2-fold difference in cell 
permeabilisation between the two strains already after 15 min of incubation, and that 
the difference increased after 30-60 min of incubation to a roughly 3 times lower 
number  of  permeabilised  HCR1  cells  compared  to  HB101  cells.  The  lower 
permeabilisation  rate  of  the  mutant  cells  seems  a  natural  consequence  of  the 
decreased binding of LL-37 to those cells (see Fig. 19).
Increasing  2  times  the  peptide  concentration  resulted  in  an  almost  3-fold 
difference in the permeabilisation of HB101, compared to only a 2-fold difference 
with HCR1,  which was another  proof  of  a  decreased  susceptibility of  the  waaY-
mutant to LL-37.
6. HCR1 was not less susceptible to the orangutan orthologue of LL-37
A growth kinetics assay was conducted to check whether the resistance to LL-
37 acquired by HCR1 could also be detected with ppyLL-37, a less active orthologue 
of  the  human  cathelicidin  from the  Bornean  Orangutan  (Fig.  21).  In  parallel,  a 
ΔwaaY strain named JW3600 from the Keio knock-out mutant collection  (Baba  et  
al., 2006) was tested along with its wild type BW25113 (Fig. 22).
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Figure  20: Uptake of propidium iodide (PI), indicating cell permeabilisation, of  HB101 and HCR1 
after  15-60  min  of  incubation  with  LL-37  at  two  different  concentrations.  With  both  peptide 
concentrations applied, the percentage of permeabilised HCR1 cells was significantly lower than that  
of HB101. This is likely due to lower peptide binding by the former cells (see Fig. 19). Asterisks mark 
the results that were statistically significant with 0.5  µM LL-37 (black) and 0.25 µM LL-37 (red), 
according to the unpaired t-test with the threshold P value of 0.05.
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RESULTS
The treatment with 1 µM ppyLL-37 produced similar growth inhibition of both 
strains (Fig. 21B), maintaining a 30% growth advantage of HB101 over HCR1 from 
the control (Fig.  21A). Incubation with 2 µM ppyLL-37 led to an equal and almost 
complete inhibition of both strains (Fig. 21C).
Surprisingly,  with  the  generally faster-growing strains  BW25113/JW3600,  a 
growth  advantage  in  favour  of  the  ΔwaaY mutant  was  observed  at  both  peptide 
concentrations applied (Fig.  22B and C), opposing the behaviour of HB101/HCR1. 
Thus, the first conclusion of no resistance to ppyLL-37 in the waaY-knock-out strains 
became inappropriate, and apparently the difference in general cell fitness of the two 
systems tested played a decisive role in the generation of opposing results. Still, a 
difference in bacterial growth in the presence of LL-37 and ppyLL-37 was observed.
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Figure 21: Growth kinetics of HB101 and HCR1 in MH broth with no peptide (A) and with 1 µM (B) 
and 2 µM (C) ppyLL-37. Equal level of growth inhibition was observed for both strains, suggesting 
that the waaY inactivation provided HCR1 with no visible resistance to ppyLL-37. Representative of 
at least three independent experiments.
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Figure 22: Growth kinetics of BW25113 and JW3600 in MH broth with no peptide (A) and with 2 µM 
(B) and 4 µM (C) ppyLL-37. In this case, lower level of growth inhibition was observed for JW3600 
(ΔwaaY), implying that the higher general fitness of the BW25113/JW3600 strains compared to that of 
HB101/HCR1 may have determined different results obtained in both assays.  Representative of at 
least three independent experiments.
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DISCUSSION
1. Mutagenesis using Tn5 complex
E.  coli HB101  strain  was  chosen  for  mutagenesis  because  it  is  highly 
susceptible to AMPs and can be transformed with a high efficiency. The strain is a 
hybrid  between  E.  coli K12  strain  AB266  (98%)  and  E.coli B,  and  the  most 
important  characteristic  of  this  strain  is  the  inactivated  recombinase  A (RecA), 
making it a stable carrier of artificially introduced DNA, though it also possesses 
impaired DNA repair ability and high UV sensitivity (openwetware.org).
A  library  of  mutants  was  produced  using  the  EZ-Tn5™  <KAN-2>  Tnp 
Transposome  kit  (Epicentre  Biotechnologies).  Mutations  were  induced  in  the 
bacterial genome by insertions of Tn5 transposon. The insertions were random and 
single per genome, as verified by Southern blot analysis (see Fig. 9, p. 64).
The best-known genome of E. coli is that of the K-12 substr. MG1655 strain. It 
contains 4,603 known genes, coding for 4,415 proteins and 188 non-coding RNAs. 
Additionally, there are 115 pseudogenes (ecocyc.org, Keseler et al., 2009). Efficiency 
calculations  of  the  number  of  mutants  generated  with  the  total  amount  of  the 
transposon-transposase complex available indicated that approx. 59,000 clones were 
generated.  Therefore,  having  obtained  a  clone  number  exceeding  the  number  of 
genes almost 13 times, we can predict a very high probability of interruption of every 
single gene in the mutant library.
Electroporations of competent cells, with an efficiency of >108 transformants 
per  µg  of  DNA,  yielded  almost  0.6  x  105 mutant  clones,  using  0.2  µg  of  Tn5 
complex. This efficiency is in close agreement with that indicated by the kit supplier 
(>105 kanamycin-resistant CFUs/µg).
The  stability  of  Tn5  transposition  and  the  ease  of  subsequent  mutant 
identification are the most important features of the method presented in this thesis. 
In  order  to  identify  the  mutation  sites,  we  decided  not  to  follow the  producer's 
instructions suggesting direct sequencing on the template of genomic DNA. Instead, 
we digested mutant genomes leaving the transposon intact and cloned the fragments, 
selecting  the  subsequently  transformed  bacteria  with  ampicillin  and  kanamycin 
which allowed us to distinguish the cloned fragments interrupted by Tn5. Although 
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this  step  consumed  a  few days,  it  facilitated  significantly  the  sequencing  of  the 
fragment, with no resequencing required in any case.
Another essential advantage of Tn5 mutagenesis is the stability of the insert. 
No kanamycin was used with the solid media containing antimicrobial peptides in 
the  selection  procedures.  This  way,  potential  interference  between  the  antibiotic 
molecules  and AMPs was avoided,  which  was particularly useful  in  light  of  the 
peptides'  sensitivity  to  the  medium  ingredients  (discussed  later).  Furthermore, 
kanamycin concentration was decreased from 50 to 25 µg/ml in the refresh cultures, 
since  it  was  observed that  the  culture  growth was slowed down with the  higher 
antibiotic concentration (results not shown). This permitted an equal growth of the 
mutant and the wild-type cultures with no detectable problems with maintaining the 
mutant phenotype.
An alternative method of generating random mutations in bacteria is based on 
the  mutagenic  activity  of  agents  such  as  N-methyl-N'-nitro-N-nitrosoguanidine 
(MNNG). This is an alkylating agent causing methylation of guanine and inducing 
the  transition  G:C→A:T,  thus  creating  point  mutations.  It  has  been  reported  to 
generate tumoral transformation in many organisms and there is also some evidence 
of  tumorigenesis  in  humans  (IARC,  1987).  MNNG as  an  experimental  bacterial 
mutagen has been described by  Miller (1992) and applied in a previous series of 
experiments  in  our laboratory  (Mattiuzzo  et  al.,  2007).  The whole procedure has 
been described by Scocchi et al. (2008).
One of the advantages of this approach is that the generation of point mutations 
results in a broader range of effects. In fact, while insertional mutations only knock-
out single genes, the application of MNNG might alter the gene in many ways, for 
instance, by single amino acid substitutions or by modifying the levels of protein 
expression through mutations in the promoter region.
On the other hand, the disadvantages seem to be more important. Firstly, the 
toxicity of the mutagenic compound poses a serious health threat not only to the 
person conducting the experiments, but also to other operators of the microbiological 
hood. Environmental safety raises difficulties in the disposal and storage of the waste 
generated in such experiments.  Secondly,  the number of mutations generated this 
way needs to be monitored and optimised to avoid creating mutants with several 
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mutations, since the identification of cumulative effects  may require unacceptable 
amounts of time and work. Finally, determining the mutation site requires isolation 
of the mutated fragment e.g. by creating a genomic library and transforming the wild 
type in order to induce the mutant phenotype, or by transforming the mutant with a 
wild-type  genomic  library  to  complement  a  recessive  mutation.  Both  procedures 
require a reselection using the selecting agent (in this case an antimicrobial peptide), 
which increases the costs and may be time-consuming.
It is important to note, that the range of genes mutated by transposon insertion 
is limited to those not essential for the cell to survive and divide. The cell carrying 
mutation  in  a  housekeeping  gene  die  and  are  not  included  in  the  final  pool  of 
mutants.
2. Test selection with Bac7(1-16)
A selection  of  Tn5  mutants  on  a  solid  medium  was  first  performed  with 
Bac7(1-16), an active fragment of Bac7. This was performed to utilise the newly 
established procedure under previously applied conditions in order to verify if similar 
results  could  be  obtained.  Furthermore,  the  test  was  conducted  to  confirm  the 
findings of Mattiuzzo et al. (2007) and possibly to appoint other potential interactors 
of Bac7. Because of the fact that the new method was capable of delivering more of 
easily identifiable gene candidates at a time, 5  µM Bac7 was used as the selective 
peptide concentration, which was  half of the peptide quantity used in the previous 
experiment  (10  µM).  The purpose of this  was to  find the genes  whose mutation 
would provide a lower grade of resistance, but which may still be involved in the 
mode of action of Bac7.
2.1. Identified resistant clones
The selection led to the isolation of 11 clones (Fig. 23), named B7R1-11, that 
were identified using the described procedure.
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Seven of these clones (B7R3-5, 7-10) carried the Tn5 insertion inside the sbmA 
gene coding for a transmembrane domain of a putative ABC transporter, which had 
been proposed to be involved in the internalisation of proline-rich peptides (PRPs) in 
the aforementioned series of experiments. In that case,  it  was shown that a point 
mutation, leading to an amino acid substitution in a conserved cytosolic loop region 
responsible  for  the  interactions  with  an  ATPase  subunit,  decreased  the  MICs  of 
several  non-lytic  PRPs  [Bac7(1-35),  Bac5(1-31),  PR-39(1-18)]  and  reduced  the 
internalisation of Bac7(1-35) by the mutant cells, compared to the wild type. The 
same effect was obtained with a  ΔsbmA strain. The lack of functional  SbmA also 
decreased the susceptibility to the glycopeptide antibiotic bleomycin. Conversely, a 
trans-complementation of the mutation restored the wild-type levels of susceptibility 
to both agents. It was finally proposed that the ABC transporter containing SbmA as 
the transmembrane subunit might be the “gate” in the plasma membrane for the non-
lytic PRPs, which can then interact with intracellular targets (Mattiuzzo et al., 2007).
Having confirmed the previous findings, we focused on the other 4 mutants 
carrying the transposon in different sites.
In B7R1, Tn5 insertion inactivated the yehY gene, a member of the yehZYXW 
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Figure 23: Transposon insertion sites identified in the B7R mutant clones selected with Bac7(1-16).  
Red arrows indicate the transposon insertion sites within appropriate genes.
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operon. The operon encodes a putative ATP-dependent osmoprotectant uptake system 
from the ABC transporter family. YehX is an ATP-binding component, YehW and 
YehY  are  membrane  components,  and  YehZ,  previously  called  OsmF,  is  a 
periplasmic binding protein. The transcription of  yehZYXW is induced by osmotic 
shock and entry into the stationary phase (Checroun and Gutierrez, 2004).
Transposon insertion in B7R2 was located in the  yjhT gene,  also known as 
nanM, which  is  the  second  element  of  the  nanC-namM-yjhS transcription  unit 
(Condemine et al., 2005). YjhT is a mutarotase of N-acetylneuraminate, allowing an 
efficient use of the compound as the sole source of carbon (Severi et al., 2008).
The B7R6 clone carried Tn5 in an intergenic sequence, directly after the phnP 
gene (not interrupting its stop codon) and 148 bp after the yjdP gene. The former is 
the last member of a 14-gene-long operon (phnCDEFGHIJKLMNOP) responsible 
for the use of phosphonates and phosphites as phosphorus sources and induced by 
phosphate starvation. The  phnP gene codes for an accessory protein to the carbon-
phosphorus lyase complex  (Metcalf and Wanner, 1993; Metcalf and Wanner, 1991; 
Yakovleva et al., 1998). The yjdP gene (erroneously called phnQ in the past) encodes 
a hypothetical, uncharacterised protein and is positioned in a direction opposite to 
that of  phnP. The interrupted region contains a  BoxC Composite Element (BOCE) 
with two palindromic sequences called boxC (Bergler et al., 1992), whose role is not 
yet known.
Lastly, in B7R11 the insertion was detected in the  waaP gene, coding for a 
kinase phosphorylating the first heptose of the inner core of LPS, as described before 
(see Introduction  5.2.). The role of this gene in the susceptibility to AMPs, which 
underlines an interesting link between the results of the selections with Bac7(1-16) 
and LL-37, will be discussed in detail later in this section.
2.2. Assessment of the resistance
Growth  kinetics  assay  was  chosen  as  a  reference  method  for  preliminary 
estimation of the level of resistance, because it allows a real-time visualisation of the 
differences in growth velocity between multiple strains in several copies (triplicate in 
this case) at a time. It also makes it possible to distinguish small variations of the 
sensitivity that would otherwise remain undetectable, e.g. in a MIC test, or would 
require low-throughput, time-consuming and laborious procedures, as in the killing 
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kinetics assay. Obviously, it does not substitute the latter experimental techniques, it 
rather provides a method of selection of what to proceed with first.
The comparison of the growth kinetics of five B7R mutants representing each 
of the identified interruptions (Fig. 10, p. 65), in the presence of Bac7(1-16), showed 
that only the  sbmA-mutant (B7R3) and, unexpectedly, the intergenic region-mutant 
(B7R6) presented a growth superior to that of the wild type (HB101), whereas other 
tested  clones  behaved  similarly  to  HB101  with  both  applied  concentrations  of 
Bac7(1-16). It is also interesting, that the two mutants grew more slowly than the 
wild type in the control incubation with no peptide. Additionally, the B7R11 clone 
was characterised by a particularly low fitness under all conditions applied.
A visible difference in growth between B7R3 and HB101 was expected in light 
of the previously discussed results by Mattiuzzo et al. (2007). However, the fact that 
all the other isolated mutants, except one, presented no difference to the wild type 
cannot be easily interpreted. It can be explained either by the failure of the growth 
kinetics assay to detect lower resistance levels, or by growth on solid medium of 
some non-resistant clones in the process of selection. Whichever the case may be, the 
results of the experiment strongly confirm that SbmA plays a key role in the peptide's 
mechanism of action.
The observed decreased level of sensitivity in B7R6 is even harder to interpret, 
given that  no  gene  is  known to  be  localised  between the  phnP and  yjdP genes. 
Transcriptional  analysis  of  the  flanking  region  could  shed  light  on  whether  the 
transposon insertion has either inactivated an unknown transcription unit, or impaired 
a presently unknown function of one of the two boxC palindromic sequences present 
in this intergenic region.
Since the purpose of this selection was to test the method of identification of 
potential AMP interactors, no subsequent experiments were performed with the B7R 
mutant  clones.  Instead,  the  same  procedure  was  applied  in  a  broader  series  of 
experiments  in  search  of  E.  coli mutations  conferring  resistance  to  the  human 
cathelicidin LL-37. This peptide shows in fact a different mode of action, a broader 
antimicrobial spectrum and high relevance for the human physiology.
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3. Application of the method in search of bacterial interactors of LL-37
3.1. Establishing the proper peptide concentration for plate selection
One of the biggest problems regarding the use of antimicrobial peptides in the 
microbiological assays is their sensitivity to the composition of the growth medium, 
mainly salts,  that modify the peptides'  conformation (see Introduction  4.2.1.)  and 
thus alter their ability to bind bacterial cells and to exert their bactericidal activity. 
Moreover, the minimal inhibitory concentrations of AMPs on solid agar media are 
usually higher than those obtained in liquid media with the same composition. For 
example, in an unpublished series of experiments aimed at selecting mutants resistant 
to the human β-defensin 3, according to Scocchi et al. (2008), it was impossible to 
obtain  repeatable  results  in  the  selection  of  peptide-resistant  mutant  cells.  The 
number of grown colonies was very high, suggesting that the selection did not occur 
because the peptide was poorly active in the solid medium, even though a diluted 
minimal  medium was  used  (25%  M9)  and  agar  was  substituted  with  ultra-pure 
agarose as a solidifying agent.
As there was a possibility of experiencing such problems also with the human 
cathelicidin, a broad range of peptide concentrations was used in the selection of LL-
37-resistant  mutants  on a  solid  medium. A hundred thousand cells  from the Tn5 
mutant library were spread on MH agar media supplemented with 1, 5, 10, 20 and
30 µM LL-37. The lowest applied concentration was equal to the MIC in liquid MH 
broth (result not shown). As expected, 1 µM concentration, similarly to three higher 
concentrations applied (5, 10 and 20 µM), led to no or insufficient reduction in the 
CFU  number.  Only  the  highest  (30  µM)  peptide  concentration  produced  a  low 
number  of  colonies  (20),  which  indicated  the  desirable  grade  of  selection  with 
respect  to  the  control  with  the  wild-type  strain.  A schematic  presentation  of  the 
selection  results  varying  according  to  the  peptide  concentration  is  shown  in
Figure 24.
85/111
DISCUSSION
LL-37, as expected, proved to be medium-sensitive and only a dose of 30-fold 
the MIC value allowed an effective selection of low-susceptibility mutants from the 
library. In comparison, Bac7 required only a 5-10-fold (this work and Mattiuzzo et  
al. 2007) peptide excess over the MIC value.
3.2. Identified resistant clones
To reduce the amount  of time and funds (e.g.  for sequencing)  necessary to 
identify  the  20  clones  that  survived  the  selection  with  30  µM  LL-37,  a  pre-
identification step was added to the procedure, based on the Southern hybridisation 
of digested genomes of the resistant clones with a Tn5 probe. The assay allowed us 
to distinguish 6 different hybridisation profiles, one of which was observed in 15 
mutants (Fig.  11,  p.  67).  The further cloning,  ampicillin/kanamycin selection and 
plasmid insert sequencing procedure was applied only to 7 clones, representing each 
of  the  obtained  hybridisation  profiles,  with  two  clones  representing  the  most 
prevalent profile. The identity of the remaining mutants showing the latter profile 
was confirmed by PCR amplification analysis  (Fig.  12,  p.  68).  All  the identified 
insertion sites are listed in Figure 25.
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Figure 24: Scheme of the CFU number reduction obtained in the selection of Tn5 mutant library on  
MH agar enriched with LL-37 at five different concentrations (indicated above each plate). Only on 
the medium with 30 µM peptide a usable number of CFUs was obtained.
1 µM 5 µM 10 µM 20 µM 30 µM
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In 15 out of 20 isolated resistant clones, the gene inactivated by Tn5 insertion 
was  waaY (rfaY), coding for one of the kinases involved in the phosphorylation of 
LPS  inner  core  in  enterobacteria.  As  mentioned  before,  the  WaaY  kinase 
phosphorylates the second heptose residue in the inner core (see Introduction 5.2.). 
As  the  experiments  carried  out  later  proved  the  importance  of  WaaY  for  the 
resistance to LL-37, this issue will be discussed to a greater extent further in this 
section.
HCR3 carried Tn5 inside a pseudogene named ydbA, interrupted naturally by 
two insertion sequences, IS2D and IS30C. The transposon insertion occurred in the 
former IS. No information on the product of ydbA is known.
In HCR12,  the interruption occurred in  the  ynfF gene,  a  part  of  the  ynfEF 
transcription unit encoding a putative selenate reductase (YnfF is an oxidoreductase 
subunit), reducing selenates to elemental selenium (Guymer et al., 2009). It has also 
been shown to form chimeric  complexes  with DmsB and DmsC from a DMSO-
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Figure 25: Transposon insertion sites identified in the HCR mutant clones selected with LL-37. Red 
arrows indicate the transposon insertion sites within appropriate genes. The arrows over the  waaY 
gene indicate only the insertion sites in the two mutants identified by sequencing.
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reductase heterotrimer because of its similarity to the natural complex-former, DmsA 
(Lubitz and Weiner, 2003).
Transposon insertion carried by HCR18 was located in the mdtQ (yohG) gene 
identified to be an outer membrane factor (OMF) family component of a multidrug 
efflux  system,  and  its  deletion  from the  E.  coli W3110  strain  caused  increased 
susceptibility to some antibiotics (Sulavik et al., 2001).
In the HCR19 mutant, the transposon was found inside the gadB gene, whose 
product is a subunit of a glutamate decarboxylase involved in the Glu-dependent acid 
resistance  system 2 (AR2),  which  protects  the cell  from acidic  conditions  in  the 
stomach after activation by chloride ions  (Gut  et al., 2006), and from weak acids 
formed  in  the  carbohydrate  fermentation  during  anaerobic  phosphate  starvation 
(Moreau, 2007). It is regulated antagonistically by two proteins, H-NS and GadX 
(Giangrossi et al., 2005).
The last resistant clone, HCR20, carried the mutation in the mdtE (yhiU) gene, 
which produces a subunit of the MdtEF multidrug transporter, regulated by the EvgA 
regulator (Nishino and Yamaguchi, 2002). Recently, it has been discovered that it is 
activated by the GadX regulator, whose overexpression led to an increased resistance 
to  several  antibiotics  and  SDS  (Nishino  et  al.,  2008).  This  effect  of  regulation 
indicates  a  link  between  the  aforementioned  acid  resistance  system  with  GadB 
involved and the drug efflux pump with MdtE.
Again, the isolated clones carried the mutations in genes of various functions 
and many of them were apparently not directly related to the known activity of LL-
37. It was thus essential to assess their resistance using the growth kinetics assay, 
previously chosen as a reference method, to exclude any chance of survival of the 
selection by non-resistant clones.
3.3. Assessment of the resistance
Growth  kinetics  of  six  HCR  mutants  in  the  presence  of  LL-37,  each 
representing a different interrupted gene (Fig. 13, p. 69), showed that only the waaY-
mutant (HCR1) was able to growth in the presence of peptide concentrations that 
were inhibitory for the wild type HB101 strain. All the other mutant clones behaved 
in a manner similar to HB101. Again, it is not clear whether the isolation of the other  
5 mutants with different interrupted genes was purely coincidental, or the method we 
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chose for a preliminary resistance characterisation (growth kinetics assay) had an 
insufficient resolution to visualise lower levels of resistance. However, since the only 
isolated  mutant  clone showing any noticeable  level  of  resistance carried the  Tn5 
insertion in the waaY gene, interrupted in 15 out of 20 mutant clones, further assays 
were performed only with HCR1 and with HB101 as a reference. The role of waaY 
in  E.  coli physiology,  discussed  briefly  in  the  introduction  (5.2.)  and  more 
completely  in  this  section,  indicated  its  possible  involvement  in  the  interaction 
between bacterial cell surface and LL-37.
3.4. Inactivation of the waaY gene led to a decreased bactericidal activity of 
LL-37 against HCR1
To verify whether the inserted transposon inactivated only  waaY,  or also its 
downstream genes in the waaQ operon, waaZ and waaU, an RT-PCR analysis of the 
three genes was carried out (see Results  4.1.). The results undoubtedly confirmed 
that  the  transposon  inhibited  solely  the  proper  transcription  of  waaY,  leaving 
unaltered the expression of the two downstream genes.
Furthermore, to complement the mutation, we constructed a plasmid containing 
an intact copy of waaY and a 300 bp sequence of the waaQ operon promoter, so as to 
restore in HCR1 the expression of the gene under the control of its natural regulators. 
Mutant cells transformed with this plasmid (HCR1C) showed a complete restoration 
of the wild-type phenotype, demonstrating a level of sensitivity to LL-37 equal to 
that of HB101 under the same conditions (see Fig. 17, p. 73).
Having proved the involvement of waaY in the decreased susceptibility to the 
peptide,  we  carried  out  killing  kinetics  assays  to  test  the  extent  of  increased 
resistance to LL-37. Indeed, the CFU number of the peptide-treated mutant strain 
was 100-1000 times higher than that of HB101 and HCR1C (see Fig.  18, p.  74). 
These results indicate that the mutated waaY leads to a decreased killing efficiency of 
the human cathelicidin against E. coli.
3.5. The role of waaY in the properties of LPS
As already mentioned, the  waaY (rfaY) gene is the third-to-last gene of the 
waaQGPSBORYZU (or rfaQGPSBIJYZwaaU) transcription unit (see Fig. 15, p. 72), 
which, in the MG1655 strain, is located approximately in the position of 3.806-3.796 
Mb  (Keseler  et  al.,  2009).  The operon consists  of  10 genes,  whose products  are 
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responsible for the biosynthesis of the outer core oligosaccharide and modification of 
the inner core of LPS. In particular, the waaP, waaQ and waaY genes are involved in 
the proper formation of the inner core moiety, composed mainly of heptose residues. 
It  has  been  shown  that  single  mutations  of  each  of  these  three  genes  cause 
modifications of the inner core structure. The proposed sequence of events during the 
addition  of  the  lateral  residues  of  the  inner  core  is  as  follows  (Fig.  26):
1)  phosphorylation of  HepI by WaaP; 2)  addition of  HepIII  residue to  HepII  by 
WaaQ; 3) phosphorylation of HepII by WaaY (Yethon et al., 1998). The absence of 
each of these enzymes disables the further steps. In particular, mutation of the waaP 
gene leads to a series of morphological and physiological alterations known as the 
“rough”  phenotype  and  is  responsible  for  an  increased  susceptibility  to  some 
antibiotics in  Salmonella  and loss of virulence  in vivo (Yethon  et al., 2000b). The 
waaY product has been described as the last factor in the sequence and its activity is 
no prerequisite to other reactions (Yethon et al., 1998). Therefore, the only effect of 
inactivating  the  waaY gene  is  the  lack  of  a  phosphate  residue  in  HepII  without 
alteration of the rest of the LPS molecule. The modification removes one negative 
charge  from  the  molecule's  net  charge,  which  might  decrease  the  electrostatic 
interactions between LPS and peptide molecules. This hypothesis was verified by 
flow cytometry assays.
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3.6.Binding to and permeabilisation of HCR1 cells by LL-37
Binding of LL-37 to the mutant, complemented and wild-type strain cells was 
determined by flow cytometry after culture incubation with LL-37-BODIPY®. As 
expected, HCR1 bound at least 2 times less peptide than HB101 and HCR1C (see 
Fig. 19, p. 75), confirming the hypothesis of a lower attraction between the peptide 
and the mutant cells. As a consequence of the lower binding, also the percentage of 
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Figure 26: Structure of the LPS from E. coli strains with an R1-type 
core. Core residues are designated by sugar abbreviation and number 
to  facilitate  identification.  Abbreviations  are  as  follows:  GlcN,  D-
glucosamine; Hep, L-glycero-D-manno-heptose;  P, phosphate; EtNP, 
2-aminoethylphosphate; Glc, D-glucose; Gal, D-galactose. The names 
of  the  genes  encoding  core  glycosyltransferases  and 
phosphotransferases indicate the bonds catalysed by each enzyme. The 
lateral  residues  of  the  inner  core  and the  enzymes  involved in  the 
sequence  of  their  addition  are  marked  with  red  fields  and  arrows, 
respectively (modified from Yethon et al., 2000a).
1)
2)
3)
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permeabilisation of the HCR1 cells by LL-37 was 2-3 times lower compared to that 
of the HB101 cells (see Fig. 20, p. 76).
The assays suggested an explanation for the decreased susceptibility of HCR1 
to  the  peptide.  Reduced  peptide  binding  to  the  external  surface  of  the  outer 
membrane,  likely due  to  a  decreased  negative  net  charge  of  the  LPS molecules, 
diminished to a similar extent the percentage of cell  permeabilisation,  allowing a 
higher number of the mutant cells to survive.
The overall  effect  of  modifications in  the LPS molecule determines  a mild 
increase of resistance to AMPs, such as that observed in the waaY deletion mutants. 
On the contrary, some mutations, such as deletion of the waaP gene, whose product 
adds  a  phosphate  group to  the  Hep I  residue,  may increase  the  susceptibility  to 
bactericidal  compounds such as  novobiocin and SDS  (Yethon  et  al.,  1998).  This 
effect is due to the fact that these mutants show a “deep-rough” phenotype, which 
leads to a serious reduction of the LPS molecule length due to the lack of lateral 
residues in the inner core and, in turn, to failure in the addition of the O-antigen. 
These “deep rough” mutants have a less stable outer membrane that can be easily 
penetrated by antibacterial agents. In this respect, we tested the activity of LL-37 
against eight knock-out E. coli mutants from the Keio collection (Baba et al., 2006), 
individually lacking each of the eight waaQGPSBORY genes. In these experiments, 
we confirmed the increased sensitivity to SDS in two of them:  ΔwaaG and  ΔwaaP, 
and additionally we found that the ΔwaaP mutant is hypersensitive to LL-37 (results 
not shown). This suggests that there are two parts of the LPS molecule particularly 
important for membrane stability and for permeability of the OM to antimicrobial 
agents: the O-antigen together with the outer core, whose assembly is initiated by 
WaaG, and the lateral residues of the inner core, whose addition depends on WaaP at 
the  beginning  of  the  aforementioned  WaaP-WaaQ-WaaY cascade.  Therefore,  we 
infer that the cells with a mutation in  waaP carry a form of LPS whose grade of 
interaction  with  the  peptide  may  be  even  lower  than  that  of  the  waaY mutants 
because of an additional loss of negative charge, however, the increased instability of 
their outer membrane overcomes the benefit of a lower peptide binding, and leads to 
a  higher  susceptibility.  This  observation  is  also  supported  by  the  lower  fitness 
showed in a growth kinetics assay by the B7R11 mutant in which Tn5 is inserted in 
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the waaP gene (see Fig. 10, p. 65).
In S. typhimurium, HepII in the core region of LPS may be dephosphorylated 
by  a  specific  phosphatase,  PmrG,  which  increases  resistance  to  polymyxin  B 
(Nishino  et  al.,  2006). PmrG  is  regulated  by  the  PmrA/PmrB  two-component 
regulatory system that controls the expression of proteins conferring resistance to 
AMPs,  including  modification  of  aminoarabinose  (Gunn  et  al.,  1998).  A PmrG 
homologue is also present in E. coli, although it is not yet clear if a similar regulatory 
system  is  active  in  this  species.  Nevertheless,  PmrG  is  a  potential  regulator  of 
bacterial resistance to LL-37, inducing effects that antagonise those of WaaY.
3.7. Inactivation of  waaY did not increase the resistance to  ppyLL-37 and 
other AMPs in HCR1
In order to verify whether the observed phenotype can be considered specific 
for the human cathelicidin or if  it  is  common for related peptides,  we tested the 
growth  kinetics  of  the  two  wild  type/mutant  systems:  HB101/HCR1  and 
BW25113/JW3600(ΔwaaY),  in  the  presence  of  an  LL-37-orthologue  from  the 
Bornean Orangutan, named  ppyLL-37. This peptide differs from LL-37 by only 3 
amino acid residues (Tab.  6) and is characterised by a slightly lower bactericidal 
activity (Zelezetsky et al., 2006).
Table 6: Comparison of LL-37 orthologues from human and the Bornean Orangutan.
Peptide (Species) Sequence (differences marked) Net charge
LL-37 (Homo sapiens) LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES +6
ppyLL-37 (Pongo pygmaeus) LLGDFFRKAREKIGEEFKRIVQRIKDFLRNLVPRTES +4
Data acquired from Morgera et al. (2009)
Surprisingly,  no  decreased  susceptibility  compared  to  the  wild  type  was 
observed (see Fig.  21, p.  77). This fact would suggest that the key region for the 
interaction between the phosphate residue of the second heptose of LPS inner core 
and the human cathelicidin might lie within the residues that differ in LL-37 and 
ppyLL-37. On the contrary, a  ΔwaaY strain, derived from the BW25113 strain did 
show lower susceptibility than its  wild type  in  a  medium supplemented with the 
peptide  (Fig.  22,  p.  78).  Additional  data  are  necessary to  explain this  behaviour. 
However, the fact that the subtraction of a negative charge from the LPS molecule 
altered the efficiency of the more positively charged peptide, only slightly changing 
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the efficiency of the less charged one, implies a considerable specificity of the LL-
37-LPS interaction, perhaps more dependent on the peptide's amino acid composition 
and layout, than on the net charge itself. This hypothesis is supported by the fact that 
HCR1 showed no visible resistance to  other  AMPs, such as  α-helical BMAP-27, 
BMAP-28,  SMAP-29,  and  proline-rich  Bac7(1-16)  and  Bac7(1-35)  (results  not 
shown). Moreover, Rosenfeld et al. suggested that the antimicrobial activity of LL-
37 is not correlated with its ability to neutralise LPS, and that different properties 
may be responsible for each of the activities  (Rosenfeld  et al., 2006, reviewed by 
Rosenfeld and Shai, 2006).
3.8. Unidentified resistant clones from the second selection
Repeated selection of the mutant library allowed us to isolate 24 new clones 
able  to  grow  on  a  medium  with  30  µM  LL-37.  Among  these  clones,  16  were 
identified as waaY-mutants, whereas 8 did not carry the transposon in that gene (PCR 
analysis, results not shown). Two of those 8 clones grew similarly to HCR1 in the 
presence  of  LL-37,  and three  others  showed a  lower  level  of  resistance  but  still 
higher than the wild type (Fig.  14, p.  70). Isolation of the new set of non-waaY-
mutants indicates that the selection may have to be performed more than one time to 
identify all the possible mutations conferring resistance to a certain AMP. The eight 
newly isolated mutants, and particularly those presenting some decrease in growth 
inhibition by LL-37, have now to be identified and their study might help to further 
elucidate  how  the  human  cathelicidin  interacts  with  the  enterobacterial  cell. 
Nevertheless,  in  light  of  the  fact  that  no  waaY-mutant  was  detected  among  27 
randomly chosen clones from the mutant library (PCR analysis, results not shown), 
the  prevalence  of  the  waaY mutation  in  the  selected  clones  observed  in  both 
selections  indicates  the  key  role  of  this  mutation  in  the  generation  of
an LL-37-resistant phenotype. Therefore, it was correctly considered the main reason 
for continuing the subsequent experimental work in that direction.
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Antimicrobial peptides are a promising family of natural antibiotics that have 
not generated any remarkable level of resistance in microbes over millions of years. 
This is because they target the most essential and characteristic microbial structures, 
such as the membranes, that could not and did not undergo any radical and rapid 
modifications in the course of evolution.
The goal of our research was to assemble a procedure for a possibly fast and 
high-throughput  detection  of  bacterial  factors  potentially  interacting  with  AMPs
(Fig. 27). It was meant to be based on a commercially available method of generation 
of  random  single-gene  knock-out  mutants  followed  by  the  selection  of  low-
susceptibility  clones  with  the  peptide  of  choice,  the  employment  of  molecular 
biology techniques  to detect  the mutated genes,  and the use of  several  antibiotic 
activity tests to assess the level of resistance. Further investigation, depending on the 
peptide used and the laboratory research profile, may involve experiments describing 
the  level  of  interaction  between  the  resistant  mutant  cells  and  the  peptide,  and 
additional  molecular  and  biochemical  tests  helping  to  describe  the  physiological 
context of the proposed target molecule.
The sequence of research activities, starting from the generation of the mutant 
library and continuing with the identification of clones with low susceptibility to the 
peptide of interest and with a preliminary resistance assessment, took approximately 
3 months. This is an acceptable amount of time for a potentially high quantity of 
information and a significant number of target candidates that can be gathered. The 
application of the procedure here described might be a good starting point to open 
new branches of research on AMP interactors and to create useful links between the 
results  obtained  using  this  method  and  the  one  previously  set  up  and  based  on 
chemical  mutagenesis.  Since  it  involves  the  use  of  knock  out-type  mutants,  the 
transposon insertion method may be considered complementary to other approaches. 
In  any  case,  it  provides  an  amount  of  data  sufficient  to  open  novel  research 
possibilities.
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Figure 27: Scheme of the established procedure for searching potential AMP interactors in bacteria.
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CONCLUSIONS
If a high number of clones is to be identified, the identification procedure can 
be sped up by dividing the obtained mutants into groups presenting similar Southern-
hybridisation profiles that, with a high probability, share the same mutation site. The 
possibility of identification through PCR product analysis drastically increases the 
productivity  of  the  method  and  allows  to  grade  the  mutations  that  influence 
resistance to the applied peptide to a different extent.
Last but not least, the use of Tn5 mutagenesis in the discovery of novel AMP 
targets only requires basic molecular biology techniques, such as cell electroporation, 
digestion of DNA and its ligation with a vector, and therefore requires neither high 
expenses nor any rare skills of the research staff. However, it later opens a vast range 
of  possible  directions  to  take  for  elucidation  of  the  obtained  data,  and  helps  to 
employ laboratory's full methodical potential.
Application of the established procedure allowed us to confirm the findings 
from previous experiments performed with the Pro-rich Bac7 and to begin with a 
new field of investigation with the human cathelicidin LL-37.
In  the  presented  work,  we  confirmed  the  previous  results  emphasising  the 
importance of a putative ABC transporter protein, SbmA, for the proper functioning 
of Bac7: a point mutation (Mattiuzzo et al., 2007) or interruption (this work) of the 
sbmA gene induced a resistant phenotype for this peptide. Furthermore, we found 
another site in the bacterial genome whose interruption conferred on  E. coli some 
degree of resistance to Bac7(1-16). Interestingly, it is an intergenic region containing 
a  palindromic  sequence  of  unknown function.  Even though at  present  it  may be 
difficult  to  explain,  this  result  can  be a  starting  point  to  a  series  of  experiments 
exploring the role of these palindromic sequences.
Our main object of interest and the main purpose of constructing the mutant 
library  was  the  search  for  factors  involved  in  LL-37  activity  in  E.  coli.  The 
experiments  allowed  us  to  identify  the  bacterial  gene  waaY whose  inactivation 
resulted in a decreased susceptibility to the human cathelicidin. Comparison of this 
result with published data permits to hypothesise that the phosphorylation of one of 
the residues  of the LPS inner  core may be an important  factor  in the interaction 
between the peptide and bacterial  outer  membrane.  This behaviour  was observed 
97/111
CONCLUSIONS
only with the human cathelicidin, while no resistance to other AMPs, both α-helical 
and  Pro-rich,  was  detected.  Thus,  we  may  have  discovered  a  moiety  of  LPS 
specifically responsible for the interactions with LL-37.
The second screening allowed the selection of clones with a level of resistance 
similar to or slightly lower than that of HCR1. Regardless of which genes have been 
isolated in the newly identified clones, the novel selection did not reproduce exactly 
the result of the first one, although the prevalence of waaY-mutants was confirmed. It 
is thus suggested to repeat the selection process since a single gene may not represent 
the whole view except in the case of prevalent mutations.
The  search  of  structures  responsible  for  microbial  susceptibility  to 
antimicrobial peptides complements the investigation of the AMPs' structure-activity 
relationship.  Our  procedure  permits  a  high-performance  and  relatively  rapid 
identification of bacterial interactors that can later help to explain the mode of action 
of AMPs of interest, so as to facilitate the generation of novel antibiotic drugs to treat 
the emerging multi-resistant infections.
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